WiLAN (WILN) Provides Litigation Update

Markman Order issued in Texas litigation with Apple and other defendants

OTTAWA, CANADA–(Marketwired – April 12, 2013) – Wi-LAN Inc. (“WiLAN” or the “Company”) (TSX:WIN)(NASDAQ:WILN) today announced that Judge Rodney Gilstrap of the U.S. District Court for the Eastern District of Texas issued a claims construction Opinion and Order, on April 11, 2013 in ongoing litigation between WiLAN and defendants Apple, Inc., Dell Inc., Hewlett-Packard Company, HTC America, Inc., Novatel Wireless, Inc., Sierra Wireless America, Inc. and several of their affiliates.

In the litigation, WiLAN is alleging infringement of U.S. Patent Nos. RE37,802 and 5,282,222 (collectively, the “Patents”). The claim construction hearing, also known as the Markman hearing, with respect to these Patents was held before Judge Gilstrap on March 21, 2013.

“After reviewing the result with outside counsel, we are pleased with the ruling and view it as a positive outcome for WiLAN,” said Jim Skippen, President & CEO.

The trial in this litigation is scheduled to begin on October 7, 2013.

WiLAN is represented in this action by McKool Smith, a leading U.S. law firm specializing in intellectual property litigation.

About WiLAN

WiLAN, founded in 1992, is a leading technology innovation and licensing company. WiLAN has licensed its intellectual property to over 265 companies worldwide. Inventions in our portfolio have been licensed by companies that manufacture or sell a wide range of communication and consumer electronics products including 3G and 4G handsets, Wi-Fi-enabled laptops, Wi-Fi and broadband routers, xDSL infrastructure equipment, cellular base stations and digital TV receivers. WiLAN has a large and growing portfolio of more than 3,000 issued or pending patents. For more information: www.wilan.com.

Forward-looking Information

This news release contains forward-looking statements and forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other United States and Canadian securities laws. The phrases “to begin” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements and forward-looking information are based on estimates and assumptions made by WiLAN in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that WiLAN believes are appropriate in the circumstances. Many factors could cause WiLAN’s actual performance or achievements to differ materially from those expressed or implied by the forward-looking statements or forward-looking information. Such factors include, without limitation, the risks described in WiLAN’s March 7, 2013 annual information form for the year ended December 31, 2012 (the “AIF”). Copies of the AIF may be obtained at www.sedar.com or www.sec.gov. WiLAN recommends that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of WiLAN’s forward-looking statements. WiLAN has no intention and undertakes no obligation to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and brands mentioned in this release are the property of their respective owners.

Contact Information:
For Media or Investor inquiries:
Tyler Burns
Director, Investor Relations
O: 613.688.4330 / C: 613.697.0367
tburns@wilan.com
www.wilan.com

Velti (VELT) and BlueKai Partner to Build Largest Pool of Mobile Data-Driven Audiences

Velti (NASDAQ: VELT), the leading global provider of mobile marketing and advertising technology, and BlueKai, today announced a mobile data partnership. As a result of the partnership, brands and agencies using BlueKai’s Data Activation System now have new access to Velti’s extensive mobile marketing data, allowing them to more precisely target consumers on mobile devices.

BlueKai powers the world’s most interconnected data marketplace and serves as the de facto standard for open and transparent audience data-driven targeting. Through this partnership, BlueKai will license data collected by Velti, on select publisher sites, providing marketers, brands and agencies with the ability to increase campaign reach and targeting while reducing waste on ineffective mobile spend. The aggregated data gives marketers valuable consumer insights, improving campaign relevance and consumer engagement and acquisition.

“This partnership brings together the world’s leading mobile and online data companies to give marketers a way to identify qualified mobile audiences at scale based on real consumer signals,” said Cory Treffiletti, BlueKai’s SVP of Marketing. “With this partnership, we are bringing a level of transparent targeting and depth to mobile that marketers have come to expect in online.”

BlueKai’s Data Activation System allows advertisers and marketers to create target audiences based on a combination of in-depth first-party and third-party audience data and activates them for all online marketing activity. Partners can accurately target campaigns to these audiences across third-party ad networks and exchanges and measure with accuracy which campaigns performed the best across segments and channels to refine their media buys and ad creatives over time. Velti’s Mobclix Exchange, through which BlueKai will access Velti’s data, is the largest real-time bidding mobile ad exchange platform and currently delivers 30 billion monthly impressions. The Exchange has access to data from 35,000 app publishers and 300 million unique mobile devices and the BlueKai Data Exchange currently has over 85 million unique users available to power more effective mobile marketing.

“Together we’re creating an industry-leading mobile opportunity for brands, agencies, publishers and anyone who wants to tap into targeted mobile advertising,” said Steve Bair, Velti’s VP of Strategic Partnerships. “With access to this data, partners can better understand their customers, maximize ad campaign performance and drive sales.”

BlueKai has also enhanced its mobile technology stack by creating the BlueKai Mobile Privacy Guard, a proprietary technology that ensures consumer anonymity without compromising any value to the marketer. Based on noise injection techniques, which are used in various fields to protect anonymity, BlueKai’s Mobile Privacy Guard will substitute random noise with value-added recommendations.

Both Velti and BlueKai have privacy policies that were designed to ensure that mobile consumer privacy remains protected at all times. The partnership will continue to maintain consumer anonymity without compromising any value to the marketer. For more information regarding Velti’s privacy policy visit: http://www.mobclix.com/privacy.html; and for BlueKai visit: http://bluekai.com/privacypolicy.php.

About Velti

Velti is the leading global provider of mobile marketing and advertising technology and solutions that enable brands, advertising agencies, mobile operators and media to implement highly targeted, interactive and measurable campaigns by communicating with and engaging consumers via their mobile devices. The Velti platform, called Velti mGageTM, allows customers to use mobile and traditional media to reach targeted consumers, engage the consumer through the mobile Internet and applications, convert them into customers and continue to actively manage the relationship through the mobile channel. Velti is a publicly-held corporation based in Jersey, and trades on the NASDAQ Global Select Market under the symbol VELT. For more information, visit www.velti.com.

About BlueKai

BlueKai (www.bluekai.com) is the world’s first complete enterprise data activation system for intelligent marketing. BlueKai offers its customers a solution for managing and activating all their 1st and 3rd party data for use in their marketing and customer interactions. BlueKai represents the only end-to-end SaaS solution for marketers who are looking to maximize their cross-channel marketing efforts and create a proprietary solution for unlocking reach, scale and efficiency in their data. BlueKai has led the data-driven marketing category since 2008 when it launched the world’s first Data Exchange and then branched out to create the first Data Management Platform (DMP) for marketers. BlueKai is currently trusted by, among thousands of others, 12 Fortune 30 corporations and numerous other brands to activate their data.

Inteliquent (IQNT) Announces Date of First Quarter 2013 Earnings Conference Call

CHICAGO, April 12, 2013 (GLOBE NEWSWIRE) — Inteliquent (Nasdaq:IQNT), a leading provider of global interconnection and interoperability solutions, announced today that it will host a conference call on Wednesday, May 1, 2013 at 10:00 a.m. (ET). Ed Evans, Chief Executive Officer, and David Zwick, Executive Vice President and Chief Financial Officer, will review the Company’s first quarter 2013 financial results and accomplishments.

Conference Call & Web Cast

The first quarter conference call will be held on Wednesday, May 1, 2013 at 10:00 a.m. (ET). A live web cast of the conference call as well as a replay will be available online on the company’s corporate web site at www.inteliquent.com. Participants can also access the call by dialing 1-877-941-0843 (within the United States and Canada), or 1-480-629-9819 (international callers). A replay of the call will be available approximately two hours after the call has ended and will be available until 11:59 p.m. (ET) on June 1, 2013. To access the replay, dial 1-800-406-7325 (within the United States and Canada), or 1-303-590-3030 (international callers) and enter the conference ID number: 4612966#.

About Inteliquent

Headquartered in Chicago, Inteliquent (operating under the legal names Neutral Tandem, Inc. and Tinet S.p.A. or the name of the applicable affiliate) provides intelligent networking to solve challenging interconnection and interoperability issues on a global scale. With an advanced MPLS network that is highly interconnected to carriers around the world, Inteliquent provides voice, IP Transit, Ethernet and hosted service solutions to major carriers, service providers and content management firms based in over 80 countries and six continents. With over 130 Ethernet sites worldwide, the Company is one of the largest global Ethernet interconnection providers, a top-five global IP Transit provider and has a leading IPv6 network. Please visit Inteliquent’s website at www.inteliquent.com and follow us on Twitter@Inteliquent.

CONTACT: Media Contact:
         Kelly Stein
         kstein@inteliquent.com.
         1-312-384-8039.

CUI Global (CUI) Announces Pricing Of $42.0 Million Follow-On Offering

TUALATIN, Ore., April 12, 2013 /PRNewswire/ — CUI Global, Inc. (“CUI Global” or the “Company”) (NASDAQ: CUI), a platform company dedicated to the acquisition, development, and commercialization of new, innovative technologies, today announced it has priced an underwritten public offering of 8,400,000 shares of its common stock at a price to public of $5.00 per share. Additionally, the Company has granted the underwriters the option to purchase up to an additional 1,260,000 shares of its common stock to cover over-allotments, if any, at the price to public. The offering is expected to close on or about April 17, 2013, subject to satisfaction of closing conditions.

(Logo: http://photos.prnewswire.com/prnh/20120320/FL72629LOGO)

The total gross proceeds of the offering are approximately $42.0 million. After deducting the underwriters’ discount and other estimated offering expenses payable by CUI Global, the net proceeds are expected to be approximately $39.1 million. The Company intends to use approximately £17.0 million of the net proceeds of the offering, or $26.2 million based on the exchange rate of $1.5385 = £1.0000 as of the New York market close on April 11, 2013, to fund the purchase price of Orbital Gas Systems Limited (“Orbital-UK”). It intends to use the remaining net proceeds to pay down approximately $2.0 million of its long term debt, as well as for working capital and general corporate purposes.

Craig-Hallum Capital Group LLC is acting as sole book-running manager of the offering. Merriman Capital, Inc. is acting as co-manager of the offering.

A registration statement relating to shares of the common stock of CUI Global has been declared effective by the Securities and Exchange Commission. This offering is being made by CUI Global by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus for the offering may be obtained from Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, phone number (612) 334-6300, or from Merriman Capital, Inc. at 135 East 57^th Street, 24^th Floor, New York, NY 10022, phone number (646) 292-1400.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CUI Global, Inc.
Delivering Innovative Technologies for an Interconnected World . . . . .

CUI Global is a publicly traded platform company focused on the acquisition and development of innovative companies and technologies. From its Vergence GasPT2 platform targeting the energy sector, to its subsidiary CUI Inc.’s digital power platform targeting the networking and telecom industries, CUI Global has built a diversified portfolio of leading technologies that touch many markets.

About CUI, Inc.

CUI Inc. is a technology company dedicated to the development and distribution of electro-mechanical products. Its broad power and component product portfolios allow customers to address design challenges across a range of industries and applications. Built on a solid foundation of core operating principals, CUI seeks to maximize value for customers through their engineering, manufacturing, and supply chain capabilities. As an industry leader, CUI continues to invest in the future through new technologies, talented employees, expanded manufacturing capabilities, and a growing global reach.

For more information, please visit www.cuiglobal.com and www.cui.com.

Important Cautions Regarding Forward-Looking Statements
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the company’s pending acquisition of Orbital-UK, the integration of Orbital-UK, the anticipated financial results of the combined company and the combined company’s anticipated marketing and sales efforts, are all subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, completion of the pending acquisition of Orbital-UK and the successful integration of the two businesses, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission, including the most recent annual report on Form 10-K.

CAMAC Energy (CAK) Announces Year End and Fourth Quarter 2012

HOUSTON, April 12, 2013 /PRNewswire/ — CAMAC Energy Inc. (NYSE MKT: CAK), a U.S.-based energy company engaged in the exploration, development and production of oil and gas in Africa, today announced a net loss of $2.9 million, or $0.02 per diluted share for the quarter ended December 31, 2012.  For the same period in 2011, CAMAC Energy reported a net loss of $1.7 million, or $0.01 per diluted share.  For the year ended December 31, 2012, CAMAC Energy reported a net loss of $6.1 million, or $0.04 per diluted share, as compared to a net loss of $24.9 million or $0.16 per diluted share, for the year ended December 31, 2011.  The decrease in net loss for the year 2012 was primarily due to lower workover costs related to well #5 in Oyo Field.

Chairman and Chief Executive Officer Dr. Kase Lawal commented, “During 2012, the Company acquired six promising exploration blocks in Gambia and Kenya, assumed technical operatorship of its Nigerian blocks OML 120 and 121, divested its China asset, and worked alongside its partner Allied Energy Plc. (“Allied”) to engage contractors for the drilling of Oyo well #7. As a result of these achievements, CAMAC Energy is currently poised to create significant value for shareholders over the next twelve months by increasing gross production from Oyo, exploring the deeper Miocene in OML 120 and 121, and conducting critical pre-drilling work in Kenya and the Gambia. We expect these activities, along with our ongoing business development program, to improve the cash flow, asset value, and market profile of the Company for the benefit of all our stakeholders.”

Operating revenues for the Company were $16.6 million for the year ended December 31, 2012, compared to $37.9 million in 2011. The decrease in 2012 was primarily due to the reduction in Cost Oil recovery related to workover costs incurred on well #5 in Oyo Field in 2010 and 2011. During 2012, the Company’s average daily gross production was 2,759 barrels of oil per day compared to 3,714 barrels of oil per day in 2011. The Company’s share of average daily net production was 401 barrels of oil per day in 2012 versus 923 barrels of oil per day in 2011. The average sales price per barrel in 2012 was $112.60, compared to $112.91 in 2011.

Average daily gross oil production for the quarter ended December 31, 2012 was 2,661 barrels of oil per day, versus 3,226 barrels of oil per day during the fourth quarter of 2011. CAMAC Energy’s net share of average daily production during the fourth quarter of 2012 was 289 barrels of oil per day compared to 680 barrels of oil per day during the fourth quarter of 2011. In the fourth quarter of 2012, there was one oil lifting from Oyo Field of approximately 251,000 barrels compared to one lifting of approximately 400,000 barrels of oil for the same period in 2011.

General and administrative expenses were $11.0 million for 2012, compared to $13.3 million for 2011.  The decrease in 2012 was primarily due to lower salary and benefits and lower stock-based compensation.

Cash and cash equivalents on December 31, 2012 were $3.8 million compared to $13.6 million for the same period in 2011. The decrease in cash and cash equivalents in 2012 was principally due to lower revenues from the Oyo Field during the year.

Estimated net proved reserves at the end of 2012 were approximately 3.1 million barrels of oil, as compared to approximately 2.7 million barrels of oil at December 31, 2011.  The Oyo Field accounted for 100% of the proved reserves.

Update on Operations

Kenya

CAMAC Energy recently announced that it has signed an agreement with Sander Geophysics Limited (“SGL”) to shoot airborne gravity and magnetic geophysical surveys on its Kenya onshore Lamu Basin Blocks L1B and L16. The data acquisition will cover essentially the entire 12,129 square kilometers in Block L1B and the entire 3,613 square kilometers in Block L16, exceeding the first exploration period’s gravity and magnetic survey requirements for each block. The results of the airborne gravity and magnetic survey will be used to optimize the placement of 2-D seismic lines. SGL commenced data acquisition this month, with initial results expected in the third quarter of 2013. The Company is also continuing to evaluate existing seismic data on Block L1B to identify leads and prospects.

On its Kenya offshore Blocks L27 and L28, the Company is undertaking a regional geological study in advance of its participation in a 2-D multi-client seismic acquisition covering both blocks sponsored by the Kenyan Government. The Company expects the acquisition to commence within the next twelve months.

The Gambia

In The Gambia, the Company currently is undertaking a geological and geophysical study in addition to evaluating existing 2-D seismic over its offshore Blocks A2 and A5 in order to delineate its 3-D seismic acquisition program.

OML 120 and 121

In the second half of 2012, CAMAC Energy assumed technical operatorship of OMLs 120 and 121 (the “OMLs”) through a technical services agreement with its partner Allied, which acquired the remaining 40% working interest in the OMLs from Nigerian Agip Exploration, a subsidiary of Eni SpA in June 2012. Since assuming technical operatorship, the Company, working alongside Allied, has stabilized Oyo Field production, contracted several reputable service companies to support the drilling of Oyo well #7, and secured the use of the Sedneth 701 semi-submersible rig, currently under contract to Nigerian Petroleum Development Corporation (“NPDC”) and operated by a unit of Transocean Ltd. (“Transocean”). The Sedneth 701 will be assigned to Allied between April and August of 2013 to drill Oyo well #7, which is being designed to both increase production from the currently producing Pliocene reservoir and explore the resource potential in the deeper Miocene reservoir.

NPDC has agreed to provide written notice to Allied thirty days prior to assignment of the rig. Transocean will continue to operate the rig during the assignment period. The Company expects drilling operations to conclude approximately sixty days from the spudding of the well. First production from Oyo well #7 is expected in the fourth quarter of 2013 upon delivery of previously ordered long-lead items related to well completion.

The Company is also in the process of re-interpreting the existing 3-D seismic data on the OMLs to identify new exploration prospects outside of the Oyo Field. The Company expects this analysis to result in an increase to the gross unrisked resource potential of the OMLs, currently estimated at over 2 billion barrels of oil by independent reserve auditors.

Conference Call Details

A conference call for investors will be held today at 10:00 a.m. Central Time (11:00 a.m. Eastern Time) to discuss CAMAC Energy’s operations and fourth quarter results with a focus on the Company’s future strategy.  Hosting the call will be Dr. Kase Lawal, Chairman and Chief Executive Officer, and Earl McNiel, Chief Financial Officer.

The call can be accessed live over the telephone by dialing, (877) 317-6789, or for international callers, (412) 317-6789.  A replay will be available shortly after the conference call and can be accessed by dialing (877) 344-7529, or for international callers, (412) 317-0088.  The passcode for the replay is 10026061.

Interested parties may also listen to a simultaneous webcast of the conference call by accessing the Investors–Events & Presentations section of CAMAC Energy’s website at www.camacenergy.com.  A replay of the webcast will be available for approximately 30 days.

About CAMAC Energy Inc.

CAMAC Energy Inc. (NYSE MKT:  CAK) is a U.S.-based energy company engaged in the exploration, development and production of oil and gas.   The Company’s principal assets include rights to interests in OML 120 and OML 121, offshore oil and gas leases in deep water Nigeria which include the currently producing Oyo Oilfield, and six recently acquired exploration blocks in Kenya and The Gambia. The Company is currently pursuing further additions to its exploration portfolio in East and West Africa.  The Company was founded in 2005 and has offices in Houston, Texas, Nairobi, Kenya, Banjul, Gambia and Lagos, Nigeria.

Forward-Looking Statements

This press release may contain certain “forward-looking statements” relating to the business of CAMAC Energy Inc. and its subsidiaries.  All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the general ability of CAMAC Energy Inc. to achieve its commercial objectives; the business strategy, plans and objectives of CAMAC Energy Inc. and its subsidiaries; resource potential; and any other statements of non-historical information.  Words such as “anticipates,” “expects,” “plans,” “projects,” “believes,” “seeks,” “estimates,” and similar expressions are intended to identify such forward-looking statements.  The statements are based upon management’s current expectations, estimates and projections, are not guarantees of future performance, and are subject to a variety of risks, uncertainties and other factors, some of which are beyond CAMAC Energy Inc.’s control and are difficult to predict, including those discussed in CAMAC Energy Inc.’s periodic reports that are filed with the SEC and available on its website (http://www.sec.gov).  You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Unless legally required, CAMAC Energy Inc. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Media:
CAMAC Energy Inc.
Cristy Taylor, 713-797-2940
PR@camacenergy.com

or

Investor Relations:
Jason Lee
832-209-1419
IR@camacenergy.com

Cardiome (CRME) Announces Share Consolidation Effective April 12, 2013

VANCOUVER, April 12, 2013 /CNW/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that effective as of the opening of trading on April 12, 2013, the Company’s share capital will begin trading on a post-consolidated basis under the same stock symbol. The Company’s transfer agent, Computershare Investor Services Inc., is in the process of mailing letters of transmittal to registered shareholders. The letter of transmittal describes the process by which shareholders may obtain new certificates representing their consolidated common shares. Shareholders who hold their shares through a broker or other intermediary and do not have shares registered in their name will not need to complete a letter of transmittal. No fractional shares will be issued under the share consolidation, and any fractional share will be rounded down to the nearest whole number. Following the consolidation, Cardiome will have approximately 12,470,335 common shares issued and outstanding. All outstanding options of the Company will be adjusted accordingly to reflect the share consolidation.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS^TM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

T3 Motion (TTTM) Prepares to Launch New T3 Vision Series Personal Electric Vehicle

www.t3motion.com – T3 Motion, Inc. (NYSE MKT: TTTM) the dominant leading provider of EV technology to law-enforcement and government markets, today announced their upcoming launch into the consumer and related markets with the development of a new personal EV, the T3 Vision™ Series, which will launch in the coming weeks. The T3 Vision™ Series, after completing rigorous beta and final field testing, has now entered full production and will be released and widely distributed throughout a new global dealer network.

“With the huge success of our professional T3 Patroller™ Series in law enforcement and commercial security applications where we hold an estimated 84% market share, we’re now prepared to launch a next generation ESV designed to fulfill the large number of requests we receive for a smaller consumer sized vehicle where we believe our superior and patented technology will once again demonstrate our ability to dominate the market.”

“As an important element of our aggressive, growth-oriented business plan the new Vision™ Series of vehicles will target new markets first by launching into the consumer market space and then also expanding us in to numerous other commercial transportation solutions. The beautiful new designs and functionality we’ve incorporated in to our T3 Vision™ Series vehicles will set new standards and offer significant advantages over any other competitive technology in the market today,” stated William Tsumpes, T3 Motion Chief Executive Officer.

“As the proven leader in Electric Standup Vehicles technology T3’s new Vision™ Series is the result of 7 years of experience in building vehicles to meet the demanding environments of government and law enforcement applications but incorporates a consumer-oriented twist, a smaller footprint and rich accessory line, resulting in a fully-customizable vehicle that will be perfectly suited for any market from airports and indoor applications to campuses, parks, RV and touring applications.”

The new vehicles will continue our proud tradition of being “Made in America.”

About T3 Motion

T3 Motion, Inc. (NYSE MKT: TTTM) designs, markets and manufactures the T3 Patroller and Vision Series Electric Stand-up Vehicles. Headquartered in Orange County, California, T3 Motion is dedicated to raising the bar on law enforcement and security capabilities in personal mobility technology. More than 4,000 T3 vehicles have been deployed in over 30 countries worldwide. For more information, visit www.t3motion.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding T3 Motion’s business, which are not historical facts, are “forward-looking statements” that are not guarantees of future performance. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others, factors associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering. For additional information concerning these and other factors that may cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Registration Statement filed on Form S-1, as amended, and in the periodic reports the Company files from time to time with the Securities and Exchange Commission.

Athersys (ATHX) to Present at Regen Med Investor Day 2013 in New York

CLEVELAND, April 11, 2013 (GLOBE NEWSWIRE) — Athersys, Inc. (Nasdaq:ATHX) announced today that Chairman and CEO, Gil Van Bokkelen, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this flagship event features sixteen of the regenerative medicine field’s leading small- and mid-cap companies. In addition, there will be disease indication focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote style talks by Jeff Jonas, President of Shire Regenerative Medicine, and Kieran Murphy, President and CEO, GE Healthcare Life Sciences.

The following are specific details regarding Athersys’ presentation at the conference:

A live video webcast of the company presentations will be available at: http://alliancerm.org/rmdaywebcast and will also be published on ARM’s website shortly after the event.

In addition to the corporate presentation, Dr. Van Bokkelen will also participate in a panel that will discuss how advanced approaches in regenerative medicine are being developed to address significant unmet medical needs in the neurological area. Athersys is focused on the development of MultiStem^® to treat acute and chronic neurological conditions, including stroke, traumatic brain injury, multiple sclerosis and spinal cord injury, as well as other programs.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem^® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including treatment of inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of inflammatory bowel disease, acute myocardial infarction, stroke and other disease indications, including lysosomal storage disorders, and the prevention of graft-versus-host disease. These risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: our ability to raise additional capital; final results from our MultiStem clinical trials; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials and obtain all necessary regulatory approvals; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones under our collaboration agreements; our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships and advance our programs; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: William (B.J.) Lehmann, J.D.
         President and Chief Operating Officer
         Tel: (216) 431-9900
         bjlehmann@athersys.com

         Investor Relations:
         Lisa M. Wilson
         In-Site Communications
         Tel: (917) 543-9932
         lwilson@insitecony.com

NTS Connects First Fiber Customer in Louisiana

NTS, Inc. (NYSE MKT/TASE: NTS) (“NTS” or “the Company”) announces that it has connected its first fiber customer in Hammond, Louisiana, marking the Company’s expansion of its fiber-to-the-premise Network (“FTTP”) into that state.

The NTS fiber build out has previously been focused on secondary markets in Texas, where the Company currently provides its fiber offerings to 15 towns, including a metro build focused on the business community in Wichita Falls. When completed, the NTS fiber network in Louisiana is expected to add approximately 11,500 passings, bringing the Company’s total FTTP passings to approximately 50,000. The Louisiana network expansion is being funded using a portion of approximately $100 million in federal stimulus funding.

Mr. Guy Nissenson, Chairman, President and CEO of NTS commented, “We are excited to have begun adding customers in our newest market, Hammond, Louisiana. As we enter new markets, we’ve typically seen strong adoption rates for our high speed triple play offering as customers recognize the value of our services, especially the high speed bandwidth. Consumers are increasingly reliant on the internet; both in residential and business applications, and the speed and accessibility of our network meets their demands. We look forward to bringing advanced broadband to more customers in Hammond during the coming weeks.”

Click here to view photo of our first customer in Hammond

About NTS, Inc.

NTS is a provider of high speed broadband services, including internet access, digital cable TV programming and local and long distance telephone service to residential and business customers in northern Texas and southeastern Louisiana. NTS’ Fiber-To-The-Premise (FTTP) network provides one of the fastest internet connections available. The Company currently has operations in Texas, Mississippi and Louisiana and also serves customers in Arizona, Colorado, Kansas, New Mexico and Oklahoma. For the Company’s website, please visit: www.ntscom.com.

This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” NTS’ financial and operational results reflected above should not be construed by any means as representative of the current or future value of its common stock. All information set forth in this news release, except historical and factual information, represents forward-looking statements. This includes all statements about the Company’s plans, beliefs, estimates and expectations. These statements are based on current estimates and projections, which involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include issues related to: rapidly changing technology and evolving standards in the industries in which the Company and its subsidiaries operate; the ability to obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new business, license and sign new agreements; the unpredictable nature of consumer preferences; and other factors set forth in the Company’s most recently filed annual report and registration statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Readers should carefully review the risks and uncertainties described in other documents that the Company files from time to time with the U.S. Securities and Exchange Commission.

BIOLASE (BIOL) FDA Clearance for the EPIC 10S Soft Tissue Diode Laser

IRVINE, CA — (Marketwired) — 04/11/13 — BIOLASE, Inc. (NASDAQ: BIOL), the world’s leading manufacturer and distributor of dental lasers, announced today that the U.S. Food and Drug Administration (FDA) has cleared the EPIC 10S™ soft tissue diode laser for use as a surgical instrument for over 80 different indications in 19 medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, orthopedics, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery (see Exhibit A for a detailed listing of medical markets and indications). The EPIC 10S is the surgical model of the recently released, next-generation dental EPIC 10™.

“We are extremely pleased to receive clearance for such a broad number of indications and procedures for our EPIC platform. The clearance for the EPIC 10S is based on the clearance we received in February 2013 for our older Diolase soft tissue diode laser and, needless to say, we are extremely happy to have received it so quickly,” said Federico Pignatelli, Chairman and Chief Executive Officer. “This clearance gives us the ability to leverage our EPIC 10™ modular soft tissue diode laser platform and consumable business across a wide range of multi-billion dollar medical markets with appropriate strategic partners or in a direct mode. With the vast number of procedures now available for the EPIC, the opportunities for this new modular platform are tremendous.”

BIOLASE’s diode lasers are currently used in dentistry for a wide variety of surgical soft tissue procedures as an alternative to invasive and traumatic conventional devices, such as the high-speed drill, scalpel, or electrosurge. The 940nm laser wavelength of the EPIC 10 platform is better absorbed by hemoglobin (Hb) and oxyhemoglobin (HbO2) than other diode laser wavelengths, so it cuts efficiently at low power and with considerably less heat and discomfort, making it an excellent alternative to conventional surgical devices. BIOLASE’s EPIC 10 940nm wavelength diode laser uses disposable tips which help reduce the risk of infection and cross contamination and is also FDA cleared for tooth whitening and temporary pain relief.

“It is truly remarkable to see how our core technologies can impact so many other medical fields. Our 940nm diode lasers are excellent alternatives to conventional surgical devices and we have already begun performing clinical studies for a variety of these new applications and some of our early results have been extraordinary,” said Fred Furry, Chief Operating Officer and Chief Financial Officer. “Our plan remains to focus on growing our core laser business in the dental market but we will also continue to expand the capabilities, applications, and indications for these core technologies in other medical markets, as well.”

Exhibit A – Detailed Listing of Medical Markets and Indications for Use

Ear, Nose and Throat and Oral Surgery:
Hemostasis, incision, excision, ablation, and vaporization of tissues from the ear, nose, throat and adjacent areas, including soft tissue in the oral cavity, such as:

• Removal of benign lesions from ear, nose and throat
• Excision and vaporization of vocal cord nodules and polyps
• Incision and excision of carcinoma in-situ
• Ablation and vaporization of hyperkeratosis
• Laryngeal papillectomy
• Excision and vaporization of herpes simplex I and II
• Neck dissection

Arthroscopy:
Hemostasis, incision, excision, vaporization, and ablation of joint tissues during arthroscopic surgery, such as:

• Menisectomy
• Syovectomy
• Chondromalacia

Gastroenterology:
Hemostasis, incision, excision, and vaporization of tissue in the upper and lower gastrointestinal tracts via endoscopy, such as:

• Hemostasis of upper and lower GI bleeding
• Excision and vaporization of colorectal carcinoma
• Excision of polyps
• Hemostasis of colonoscopy
• Hemostasis of esophageal varices

Orthopedics:

• Dissect and coagulate

General Surgery, Dermatology & Plastic Surgery, and Podiatry:
Excision, ablation, vaporization, and photocoagulation of skin lesions, hemostasis, incision, excision, vaporization, ablation, and debulking of soft tissue, abdominal, rectal, skin, fat or muscle tissue, and dermabrasion, such as:

• Matrixectomy
• Excision of neuromas
• Excision of periungual and subungual warts
• Excision of plantar warts
• Excision of Keloids
• Excision of cutaneous lesions
• Hemorrhoidectomy
• Appendectomy
• Debridement of decubitus ulcer
• Hepatobiliary
• Mastectomy
• Dermabrasion
• Vaporization & hemostasis of capillary hemangioma
• Excision, vaporization & hemostasis of abdominal tumors
• Excision, vaporization & hemostasis of rectal pathology
• Pilonidal cystectomy
• Herniorraphy
• Adhesiolysis
• Parathyroidectomy
• Laparoscopic cholecystecomy
• Thyroidectomy
• Resection of organs

GI/GU:
Excision, vaporization, and hemostasis of abdominal and rectal tissues, such as:

• Hemorrhoidectomy
• Excision, vaporization, and hemostasis of rectal pathology
• Excision, vaporization, and hemostasis of abdominal tumors

Gynecology:
Ablation, excision, hemostasis, and vaporization of tissue, such as:

• Excision or vaporization of condylomata acuminata
• Vaporization of CIN (cervical intraepithelial neoplasia)
• Cervical conization
• Menorrhagia
• Ovarian cystectomy

Neurosurgery:
Vaporization, coagulation, excision, incision, ablation and hemostasis of tissue, such as:

• Hemostasis in conjunction with meningiomas
• Percutaneous Disc Decompression (PLDD)

Ophthalmology:

• Dacryocystorhinostomy transcanalicular
• Open DCR
• Tumor Excision
• Blepharoplasty

Pulmonary Surgery:
Hemostasis, vaporization, and excision of tissue, such as:

• Tracheobronchial malignancy or stricture
• Benign and malignant pulmonary obstruction

Cardiac Surgery:

• Coagulation and hemostasis of cardiac tissue

Thoracic Surgery:

• Thoracotomy
• Pulmonary resection
• Hemostasis
• Pericardiectomy
• Adhesiolysis
• Coagulation of blebs and bullae

Urology:
Hemostasis, vaporization, incision, coagulation, ablation, and excision of tissues, such as:

• Vaporization of urethral tumors
• Release of urethral stricture
• Removal of bladder neck obstruction
• Excision and vaporization of condyloma
• Lesions of external genitalia
• Circumcision
• Vaporization of the prostate to treat benign prostate hyperplasia (BPH)

Dermatology/Aesthetics:

• Photocoagulation of vascular & dermatological lesions of the face and extremities
• Photocoagulation of telangiectasia, venulectasia of the legs and face
• Treatment of reticular veins and branch varicosities
• Pyrogenic granuloma, lymphangioma and lymphangiomatosis disease, angiofibromas
• Superficial benign vascular lesions including Telangiectasias, hemangioma, Port wine stains, angiokeratoma, and benign epidermal pigment lesions as lentigines, epidermal nevi, spider nevi
• Dermatological surgery: Condyloma acuminate, warts, small non-malignant skin tumors, small semi-malignant tumors as basaliomas, Bowe and Kaposi sarcoma, warty leucoplasty and ulcers debridement
• Seborrheic keratosis
• Mixoid cyst
• Papillary varix
• Acne treatment

Vascular Surgery:

• Photocoagulation of vascular & dermatological lesions of the face and extremities
• Photocoagulation of telangiectasia, veinulectasia of the legs and face
• Treatment of reticular veins and branch varicosities

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s laser products incorporate over 340 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 22,000 lasers. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.

Wireless Ronin (RNIN) and Delphi Display Systems Join Forces

MINNEAPOLIS, MN — (Marketwired) — 04/11/13 — Wireless Ronin Technologies, Inc. (NASDAQ: RNIN), a leading marketing technologies solutions provider, and Delphi Display Systems, Inc., a leading manufacturer of outdoor LCD-based display systems for digital signage, have entered into an exclusive licensing and services agreement to provide integrated technology solutions to the quick-service restaurant (QSR) and “pump topper” gas station markets.

Under the terms of the agreement, Wireless Ronin granted Delphi an exclusive license to use and sublicense its RoninCast® 4.0 HTML5-based software in the QSR and pump topper target markets. Delphi will market and sell the end-to-end customer engagement solutions exclusively to the QSR and pump topper markets as part of its Insight Engage™ technology platform. In consideration for the exclusive license, Delphi will pay Wireless Ronin a minimum of $2.0 million over five years, $750,000 of which to be paid within two days following execution. Delphi will use Wireless Ronin’s 24/7 network operations center exclusively to host Delphi’s digital signage applications, which will provide Wireless Ronin recurring hosting and maintenance revenue over the next five years. Wireless Ronin and Delphi have also mutually agreed to not compete with each other within and outside the target markets. Each party has agreed to refer prospective customer opportunities outside its own exclusive markets to each other to leverage the relationship.

Delphi intends to integrate Wireless Ronin’s latest RoninCast® software technology with Delphi’s Insight Engage™ drive-through technology platform to provide a full service, end-to-end customer engagement solution in the QSR and pump topper markets. The solution will be designed to address the needs of Delphi’s global installation base of more than 30,000 customers, including large franchisees of major QSRs, as well as Wireless Ronin’s current pipeline of potential customers in the QSR target market.

The fully-integrated solution will include interior and exterior digital menu boards, order confirmation, wireless communication systems and timing systems, along with cloud-based software to manage these functions and deliver performance metrics.

Wireless Ronin will provide content management and delivery, enterprise-wide real-time data aggregation, analytics and reporting, as well as integration with point of sale (POS), mobile devices, social media, and customer loyalty programs. Delphi also provides integrations with virtually every common POS platform as a key part of its business.

“This agreement marks a major strategic shift for Delphi, as we transition from an outdoor digital signage hardware provider to a world-class enterprise solutions company focused on delivering high-value, tightly-integrated hardware and software solutions to the QSR and pump topper markets,” said Ken Neeld, president and CEO of Delphi Display Systems. “We evaluated many software technologies and chose Wireless Ronin because of the robust capabilities of their well-architected platform that leverages the latest HTML5 technologies. We also share a similar vision for engaging our end-customers with a true omni-channel experience.”

Scott W. Koller, president and CEO of Wireless Ronin, commented: “The combination of Delphi’s expertise, products and services with our RoninCast software and network operations center, provides the QSR and pump topper industries a comprehensive technology solution specifically designed to address their digital signage and menu board requirements.

“This relationship not only makes a comprehensive solution available to Delphi’s existing customer base and pipeline, but also generates recurring revenue from hosting and maintenance,” added Koller. “Further, it allows us to leverage Delphi’s extensive sales and marketing efforts, enabling Wireless Ronin to focus our resources on our growing pipeline of opportunities in the automotive, retail, food service, and fast casual markets.”

About Delphi Display Systems
Delphi Display Systems, Inc. designs and manufactures a wide variety of outdoor digital signage products and business analytics software solutions serving the quick service restaurant (QSR), petroleum, retail, and other market verticals. Applications include drive-thru order confirmation systems, vehicle timing solutions, digital menu boards, gas-pump top video displays, outdoor interactive way-finding systems and more. Delphi’s has its products installed in more than 30,000 QSR locations in 49 countries. Follow the company on Twitter (https://twitter.com/DelphiDisplay) and “like us” on Facebook under Delphi Display Systems. For more information on the company and its products, visit www.DelphiDisplay.com or call 714-825-3400.

About Wireless Ronin Technologies, Inc.
Wireless Ronin Technologies, Inc. (WRT) (NASDAQ: RNIN) (www.wirelessronin.com) is a marketing technologies company with leading expertise in current and emerging digital media solutions, including signage, interactive kiosks, mobile, social media and web, that enable clients to transform how they engage with their customers. WRT provides marketing technology solutions and services to clients, helping increase revenue and improve operating efficiencies to execute marketing initiatives. Since launching RoninCast® digital signage software in 2003, WRT has led the digital signage industry by bringing leading edge technology, services and support to its clients. WRT offers an array of services to support its clients’ marketing technology needs including consulting, creative development, project management, installation, training, and support and hosting. The company’s common stock trades on the NASDAQ Capital Market under the symbol “RNIN.” Follow the company on Twitter (http://twitter.com/wirelessronin) and Pinterest (http://pinterest.com/rnin/) and “like us” on Facebook (www.facebook.com/WirelessRonin) under Wireless Ronin.

Forward-Looking Statements
This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s expectations regarding the license and service agreement with Delphi and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: estimates of future expenses, revenue and profitability; the pace at which the company completes installations and recognizes revenue; trends affecting financial condition and results of operations; ability to convert proposals into customer orders; the ability of customers to pay for products and services; the revenue recognition impact of changing customer requirements; customer cancellations; the availability and terms of additional capital; ability to develop new products; dependence on key suppliers, manufacturers and strategic partners; industry trends and the competitive environment; and the impact of losing one or more senior executives or failing to attract additional key personnel. These and other risk factors are discussed in detail in the risk factors section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2013.

Company Contact:
Scott W. Koller
President and Chief Executive Officer
Wireless Ronin Technologies, Inc.
952-564-3500

Investor Relations Contact:
Matt Glover or Michael Koehler
Liolios Group, Inc.
Email Contact

Crimson (CXPO) to Present at the IPAA 2013 Oil & Gas Investment Symposium

Crimson Exploration Inc. (NasdaqGM:CXPO) today announced that Allan D. Keel, President and Chief Executive Officer, will present at the IPAA 2013 Oil & Gas Investment Symposium at the Sheraton New York Hotel & Towers located at 811 Seventh Avenue at 53^rd Street, New York, NY 10019 on Wednesday, April 17, 2013 at 1:35 PM ET.

An audio webcast of the presentation can be accessed at http://www.investorcalendar.com/CEPage.asp?ID=170817 or by visiting the Company’s website at http://crimsonexploration.com. A copy of the presentation will be posted to the website in the “Investor Relations” section prior to the start of the Company’s presentation.

Crimson Exploration is a Houston, Texas-based independent energy company engaged in the exploitation, exploration, development and acquisition of crude oil and natural gas, primarily in the onshore Gulf Coast regions of the United States.

Additional information on Crimson Exploration Inc. is available on the Company’s website at http://crimsonexploration.com.

Synacor (SYNC) Cloud ID Social Login Continues Momentum as Customers Launch the Service

Service Providers Including Midcontinent Now Offer Synacor’s First-Of-Its-Kind Social Login, Providing Access to Online pay-TV Content Through Social Accounts Like Facebook, Twitter or Google

BUFFALO, N.Y., April 10, 2013 (GLOBE NEWSWIRE) — Synacor, Inc. (Nasdaq:SYNC), leading provider of next-gen startpages, TV Everywhere solutions and cloud-based Identity Management (IDM) services across multiple devices for cable, satellite, telecom and consumer electronics companies, today announced continued momentum of Cloud ID Social Login, a key offering of its Cloud Identity Management platform. Midcontinent is among the first service providers to offer their subscribers Social Login as a means to simultaneously authenticate for TV Everywhere content when logging in on Facebook, Twitter or Google.

“According to GfK, 70% of TV Everywhere users would be at least somewhat deterred from using TVE if they needed to provide authentication,” said Michael Bishara, Vice President and General Manager of TV Everywhere, Synacor. “We see our Cloud ID Social Login as a huge opportunity to provide a fun, friction-free solution that improves consumers’ online content access experience—all part of spurring accelerated TVE adoption.”

Social Login gives Synacor customers the flexibility to offer subscribers access to online pay-TV content with their favorite social accounts like Facebook, Twitter or Google. The offering simultaneously authorizes with the subscriber’s pay-TV provider or billing account. Synacor Cloud ID brings the convenience of Social Login to TV Everywhere consumers with the trust of entitlement verification for TV authorization.

“Through Synacor’s Social Login offering, we’re ensuring our subscribers have an easier way than ever before to access the content they want,” said Pat McAdaragh, CEO, Midcontinent. “We’re pleased to launch Synacor’s Social Login, along with their TV Everywhere and subscriber startpage offerings, which Midco subscribers already enjoy.”

Synacor’s Cloud ID Management Platform provides authentication services for TV Everywhere, Messaging, Value Added Services and Identity Management Services. These capabilities help consumer electronics companies, app developers and programmers to provide a secure and trusted identity management solution to their end-consumers.

For more information on Synacor and Social Login, please visit synacor.com or email tellmemore@synacor.com. To see Synacor’s Michael Bishara talk more about TV Everywhere, please click here.

About Synacor

Synacor’s white-label platform enables cable, satellite, telecom and consumer electronics companies to deliver TV Everywhere, digital entertainment, cloud-based services and apps to their end-consumers across multiple devices, strengthening those relationships while monetizing the engagement. Synacor (Nasdaq:SYNC), is headquartered in Buffalo, NY. For more information, visit synacor.com.

Integrate. Authenticate. Engage.

About Midcontinent Communications

Midcontinent Communications is the Upper Midwest’s leading provider of data, video, phone and cable advertising services for over 300,000 residential and business customers in North and South Dakota, Minnesota and Wisconsin.

Forward-Looking Statements

This release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of management of Synacor, and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other factors affecting the operation of the respective businesses of Synacor. More detailed information about these factors may be found in filings by Synacor, as applicable, with the Securities and Exchange Commission, including their respective Quarterly Report on Form 10-Q. Synacor is under no obligation to, and expressly disclaims any such obligation to, update or alter their respective forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Michael Zema
         (212) 445-8181
         mzema@webershandwick.com

Aeterna (AEZS) and Ergomed Sign Co-Development and Profit Sharing Agreement

QUÉBEC CITY, April 10, 2013 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced the signing of a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. (“Ergomed”) for AEZS-108 in endometrial cancer. Ergomed was selected as the contract clinical development organization to conduct the multicenter, multinational, randomized Phase 3 trial with AEZS-108 in endometrial cancer.

Under the terms of the agreement, Ergomed will assume 30% (up to $10 million) of the clinical and regulatory costs for the Phase 3 trial with AEZS-108 in endometrial cancer, which are estimated at approximately $30 million over the course of the study. Ergomed will receive its return on investment based on an agreed single digit percentage of any net income received by Aeterna Zentaris for AEZS-108 in this indication, up to a specified maximum amount.

Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, “We look forward to working with Ergomed which has a proven track record of delivering cost effective and efficient drug development services worldwide. This agreement is part of our non-dilutive strategy aimed at minimizing R&D costs while maximizing drug development efficiency. Our goal for AEZS-108 with this collaboration, is to provide a much needed new treatment option to women with late-stage endometrial cancer.”

Miroslav Reljanovic, M.D., CEO of Ergomed said, “We are delighted to co-invest with Aeterna Zentaris in the development of AEZS-108 which has shown promising results in Phase 2 trials to date. This agreement is the fifth co-development deal we have signed to date, and demonstrates again the attractive alternative it offers to sophisticated drug developers, as they look to maximise investment returns. Ergomed is now established as one of the leading companies worldwide offering and completing deals under this innovative model.”

The Study

This will be an open-label, randomized, multicenter Phase 3 trial conducted in North America, Europe, Israel and other countries under a Special Protocol Assessment, comparing AEZS-108 with doxorubicin as second line therapy for locally-advanced, recurrent or metastatic endometrial cancer. The trial will involve approximately 500 patients and the primary efficacy endpoint is improvement in median Overall Survival.

For more information on this trial, go to www.clinicaltrials.gov NCT 01767155.

About AEZS-108 (doxorubicin peptide conjugate)

AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. The product has successfully completed Phase 2 studies for the treatment of ovarian and endometrial cancer and the Company is currently planning a Phase 3 trial in endometrial cancer under a Special Protocol Assessment. AEZS-108 is also in Phase 2 trials in triple-negative breast cancer, prostate cancer and bladder cancer. AEZS-108 has been granted orphan drug designation by the FDA and orphan medicinal product designation from the European Medicines Agency for the treatment of ovarian cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108.

About Endometrial Cancer

Endometrial cancer is the most common gynecologic malignancy and develops when abnormal cells amass to form a tumor in the lining of the uterus. It largely affects women over the age of 50 with a higher prevalence in Caucasians and a higher mortality rate among African Americans. Approximately one in 30 women is diagnosed with endometrial cancer every year. According to the American Cancer Society, an estimated 49,560 new cases of endometrial cancer in the U.S., and 35,600 in Europe, are expected during 2013, with about 20% of recurring disease.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information, visit www.aezsinc.com.

About Ergomed

Ergomed offers clinical development services for the biotechnology and pharmaceutical industry specializing in therapeutics for oncology, neurology and immunology. Ergomed also engages in shared risk ventures through co-development agreements. With its global infrastructure in Western and Eastern Europe, the Middle East and North America, Ergomed offers cost effective and efficient drug development. For further information, visit www.ergomed-cro.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

DragonWave (DRWI) Announces Renewed Framework With Nokia Siemens Networks

OTTAWA, ONTARIO — (Marketwired) — 04/10/13 — DragonWave Inc. (TSX:DWI)(NASDAQ:DRWI) today announced changes to its existing operational framework with Nokia Siemens Networks. In line with the renewed framework, DragonWave will continue to be the preferred, strategic supplier to Nokia Siemens Networks of packet microwave and related products, and the companies will jointly coordinate technology development activities.

The renewed framework will strengthen the alliance between both companies. This reinforces Nokia Siemens Networks’ strong commitment to its mobile broadband customers, who will continue to enjoy a complete mobile broadband solution including FlexiPacket Microwave Radios supplied by DragonWave. With this, mobile operators will be able to further drive innovation in the high capacity E-Band and small cell domains.

Under the terms of the renewed framework Nokia Siemens Networks will provide DragonWave with an immediate cash payment of EUR10.6M. This will clear the contingent receivable on DragonWave’s balance sheet. Nokia Siemens Networks will take on additional commitments and costs so that DragonWave can continue to develop world class microwave products at competitive prices and focus on excellence in quality and supply. The Italian services agreement, pursuant to which Nokia Siemens Networks has provided R & D and certain other services to DragonWave since June 1, 2012, is terminated. As a result of this action DragonWave expects that operating costs will be reduced by approximately EUR3M per quarter. DragonWave expects to pay a termination fee totaling approximately EUR7M over the balance of fiscal year 2014.

DragonWave has rebranded the products acquired from Nokia Siemens Networks as “Harmony” products and will continue the support and development of these products, which will also be sold via Nokia Siemens Networks. The strategic agreement envisions Nokia Siemens Networks continuing to maintain the commercial interface to mobile customers and “Harmony” remains a fundamental part of its Mobile Broadband proposition.

“The new arrangements being announced today are intended to streamline our operations and customer outreach strategy to better serve Nokia Siemens Networks and its customers. We look forward to continuing to pursue market opportunities together with Nokia Siemens Networks,” said DragonWave President and CEO Peter Allen.

“We believe that, by 2020, mobile networks will need to be ready to deliver one gigabyte of personalized data per user per day profitably and we are committed to offering our customers the best mobile broadband solution possible including the microwave that DragonWave brings to the table,” added Marc Rouanne, executive vice president, mobile broadband at Nokia Siemens Networks.

In addition to the new arrangements with Nokia Siemens Networks, DragonWave confirmed that as part of ongoing cost reductions it has also recently reduced its senior management positions by 33%. An update on the overall impact of DragonWave’s cost reduction programs will be provided on DragonWave’s next results conference call.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s products is wireless network backhaul. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are identified by the use of terms and phrases such as “will”, “intend”, “believe”, “expect” or similar expressions. Forward-looking statements include statements as to potential benefits for DragonWave and its stakeholders of the renewed framework with Nokia Siemens Networks, including the expected reduction in DragonWave’s operating costs. These statements are subject to certain assumptions, risks and uncertainties, including DragonWave’s view of its ongoing preferred, strategic supplier relationship with Nokia Siemens Networks and DragonWave’s position in the marketplace, and the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contacts:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
613-599-9991 ext 2262

Russell Frederick
CFO
DragonWave Inc.
rfrederick@dragonwaveinc.com
613-599-9991 ext 2253

Becky Obbema
Interprose Public Relations
(for DragonWave)
Becky.Obbema@interprosepr.com

Royale Energy (ROYL) Announces $43,000,000 Alaska North Slope JV

Company Agrees to Fund Exploration Cost

SAN DIEGO, April 10, 2013 (GLOBE NEWSWIRE) — Royale Energy, Inc. (Nasdaq:ROYL) today announced that it has signed a letter of intent to receive $100 per acre in cash, plus other consideration including stock options and exploration cost sharing for a total of over $1,200 per acre for up to 50,875 acres of its 96,000 acre Alaska North Slope holdings.

An undisclosed company has agreed in principal to fund all exploration costs for seismic data acquisition and the drilling of two horizontal wells for a total of $38 million. Additionally Royale will receive $3,373,659 USD for the 33,736.59 acres on the company’s Western Block, together with stock options and a right to receive an additional $1.7 million USD for 17,000 acres in the company’s Central Block.

“We are pleased to have found a company that shares our vision and optimism for the potential of these important Alaska shale oil resources,” noted Stephen Hosmer, Royale Co-CEO. “This agreement will allow us to confirm participation in a planned 3D seismic data acquisition scheduled to take place later this year over our acreage.”

The focus of the exploration that results from this agreement will take place in the western block Royale acquired in December. Each well location is expected to be selected with the full support of seismic data, to test both conventional and shale oil resource accumulations anticipated to be present.

The transaction is subject to consummation of a final agreement setting forth the detailed terms of investment and the exploration of the property. The prospective agreement is still under negotiation between the parties and is expected to be completed on or before May 30 this year.

Forward Looking Statements

In addition to historical information contained herein, this news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, subject to various risks and uncertainties that could cause the company’s actual results to differ materially from those in the “forward-looking” statements. While the company believes its forward looking statements are based upon reasonable assumptions, there are factors that are difficult to predict and that are influenced by economic and other conditions beyond the company’s control. Investors are directed to consider such risks and other uncertainties discussed in documents filed by the company with the Securities and Exchange Commission.

CONTACT: Royale Energy, Inc.
         Chanda Idano, Director of Marketing & PR
         619-881-2800
         chanda@royl.com
         http://www.royl.com

VistaGen (VSTA) Announces $36 Million Strategic Financing Agreement

SOUTH SAN FRANCISCO, CA — (Marketwired) — 04/10/13 — VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp. (PINKSHEETS: BGMO), a global diversified investment holding company.

Under the terms of the agreement, Bergamo’s European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company’s self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen’s Common Stock.

VistaGen plans to use proceeds of the financing to accelerate and expand its stem cell technology-based drug rescue programs. Using its innovative CardioSafe™ 3D and LiverSafe™ 3D bioassay systems and modern medicinal chemistry, the Company is focused on generating new, safer, proprietary variants (Drug Rescue Variants) of once-promising small molecule drug candidates discontinued in development by large pharmaceutical companies due to heart or liver safety issues. In collaboration with co-founder and renowned stem cell research scientist, Dr. Gordon Keller, as well as long-term strategic partner, the University Health Network in Toronto, and several other leading academic and corporate collaborators, VistaGen also plans to advance new pilot nonclinical regenerative cell therapy programs and certain other emerging commercial opportunities related to its Human Clinical Trials in a Test Tube™ platform.

“Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process,” stated Shawn K. Singh, VistaGen’s Chief Executive Officer. “Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes.”

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen’s drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

VistaGen’s small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the satisfaction of certain conditions to closing the strategic financing referred to in this press release, the success of VistaGen’s stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems and cell therapies, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, regenerative cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or regenerative cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For more information:

Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
IR Communications
Atlanta, Georgia
www.MissionIR.com
404-941-8975

Revised Restructure, Recapitalisation and Refinancing Plan for Atlatsa (ATL)

Re-dissemination of the March 27, 2013 news release

JOHANNESBURG, April 9, 2013 /PRNewswire/ – Atlatsa Resources Corporation (“Atlatsa”) (TSXV: ATL; NYSE MKT: ATL; JSE: ATL) reports the following announcement referenced in its March 27, 2013 news release.

1. Introduction

The boards of directors of Anglo American Platinum, a 79.9% held subsidiary of Anglo American plc, Atlatsa and Atlatsa Holdings (Proprietary) Ltd (formerly known as Pelawan Investments, the controlling Black Economic Empowerment (“BEE”) shareholder of Atlatsa) (“Atlatsa Holdings”) (collectively “the Parties”) are pleased to announce that they have concluded binding definitive agreements for the revised restructure, recapitalisation and refinancing of Atlatsa and the Bokoni group of companies (“Bokoni Group”) (the “Revised Restructure Plan”).

2. Background

On 2 February 2012, the Parties announced that they had entered into a binding term sheet for the initial phase of the Restructure Plan (the “Initial Restructure Plan”).

In February 2012, the Parties also appointed a new management team at the Bokoni Platinum Mine (“Bokoni Mine”).

During 2012 the new management team at Bokoni Mine, together with the Parties, undertook a detailed strategic review of all technical, operational and financing assumptions informing the existing mine extraction and financing strategy at Bokoni Mine, having regard to both macro and micro economic factors affecting both the Bokoni Mine, as well as the PGM industry and its outlook in general (the “2012 Strategic Review”).

Based on the results of the 2012 Strategic Review the Parties undertook to implement the Revised Restructure Plan, comprising a lower-risk operating and financing plan for Atlatsa and the Bokoni Mine going forward.

On implementation of the Revised Restructure Plan (as outlined below), Atlatsa and the Bokoni Group will be well positioned to implement their business strategy on a more conservative, lower risk and sustainable basis.

The Revised Restructure Plan retains most of the elements agreed between the Parties in the Initial Restructure Plan and improves upon the Initial Restructure Plan as follows:

• A new and more conservative operating and financing plan for Bokoni Mine through to 2020.
• A simplification to the equity capital structure (as set out in paragraph 4.2 below) of Atlatsa which results in:
  • an equity capital injection into Atlatsa of ZAR 750 million (US$ 88.35 million) by Anglo American Platinum subscribing for 125 million new common shares in Atlatsa at ZAR 6.00 per share (US$0,71 cpc), the proceeds of which will be used to further reduce Atlatsa’s outstanding debt;
  • the unwinding of the historical “B” preference share arrangement, such that Atlatsa will have one class of common shares going forward; and
  • an increase in the BEE shareholding in Atlatsa from 51% to 62% (fully diluted), facilitated by Anglo American Platinum selling 115.8 million Atlatsa common shares, arising from the unwind of the “B” preference shares, to Atlatsa Holdings for ZAR 463 million (US$ 54.54 million) on a vendor financed basis.
• An amendment to the debt capital structure and financing terms of Atlatsa, which results in the following revisions to the existing debt facility between Atlatsa and Anglo American Platinum:
  • a 75% reduction in Atlatsa’s debt from ZAR 3.28 billion (US$ 386.38 million) to approximately ZAR 833 million (US$ 98.13 million), as at 31 December 2012 (see paragraph 4.2 below);
  • an increase in the existing debt facility by  ZAR 700 million (US$ 82.46 million) made available to Atlatsa to finance its 51% pro rata share of the planned expansion at Bokoni Mine through to 2020, with a maximum facility limit of ZAR1.55 billion (US$182.54 million); and
  • a reduction in Atlatsa’s estimated effective cost of borrowing from 13% to 2% over the debt term period between 2013 to 2020 (see paragraph 4.2 below).

3. Transaction Rationale

The Parties’ original intention for the creation of the Bokoni Group, first announced in 2007 and later modified in 2009, sought to transform the South African PGM mining landscape by Anglo American Platinum facilitating the transformation of Atlatsa and the Bokoni Group into a sustainable, historically disadvantaged South African (“HDSA”) controlled PGM producer.

Based on the outcome of the 2012 Strategic Review, the Parties agreed that in order to meet the original objectives for the empowerment transaction, it was necessary to implement the Revised Restructure Plan in order to place both Atlatsa and the Bokoni Group on a firmer footing.

4. Revised Restructure Plan

The key features of the Revised Restructure Plan include, inter alia:

4.1 New Operating Plan

The 2012 Strategic Review determined to scale the Bokoni Mine as a 160,000 tpm operation through to 2020, relative to its existing installed concentrator plant processing capacity. Accordingly, material capital expenditure associated with the proposed UG2 expansion plan at Bokoni Mine, estimated at ZAR 2.3 billion (US$ 270.94 million) has been deferred beyond 2020.

In an effort to further reduce unit operating costs, the 2012 Strategic Review identified certain potential Merensky open cast project opportunities which, subject to final regulatory approvals, will be exploited from 2013 onwards. This will allow the Bokoni Mine to meet its installed processing capacity in the near term with ore from both open cast and underground mining operations, whilst its underground mining operations build up from 100,000 tpm (current) to 160,000 tpm over the next five years.

On successful implementation of the new operating plan the Bokoni Mine will double its production profile from its existing base of approximately 115,000 PGM ounces per annum to 250,000 PGM ounces per annum between 2013 and 2016.

The new operating plan will result in Bokoni Mine becoming a predominantly Merensky Reef producer, accounting for approximately 70% of its total estimated production in the medium-term.

The capital cost estimate for the new expansion plan at Bokoni Mine is ZAR 1.1 billion (US$ 129.58 million) in 2012 money terms. This estimate includes capital required for the completion of the Brakfontein Merensky project and the revised Middelpunt Hill UG2 project.

Atlatsa will finance its 51% pro rata share of expansion plans at Bokoni Mine (estimated at ZAR 561 million (US$ 66.09 million) from internal cash flows generated at Bokoni Mine, together with its available credit facilities of ZAR 700 million (US$ 82.46 million) to the extent required – refer to 4.2 below.

The new operating plan at Bokoni Mine is considered a lower-risk, less capital intensive and more conservative plan from both an operational and financing perspective.

4.2 Debt and Equity Capital Restructure

Atlatsa will sell its attributable interest in the Eastern section of the Ga-Phasha project and the                   entire Boikgantsho project (comprising an estimated total of 31.4 million PGM undeveloped Resource ounces) to Anglo American Platinum for a purchase consideration of ZAR 1.7 billion (US$ 200.26 million) (“the Asset Sale”). All the proceeds received from the Asset Sale will be utilised by Atlatsa to reduce existing debt owing to Anglo American Platinum.

Anglo American Platinum will subscribe for 125 million new common shares in Atlatsa at ZAR 6.00 per share ($0.71), all the proceeds of which will be used to further reduce existing debt owing to Anglo American Platinum.

The net effect of the Revised Restructure Plan for Atlatsa is a 75% reduction in the Company’s debt as at 31 December, 2012 through a series of transactions, summarised as follows:

As per the table above, the reduced Atlatsa debt balance owing to Anglo American Platinum in terms of the existing debt facility will be approximately ZAR 833 million (US$ 98.13 million) at 31 December 2012. Anglo American Platinum will make available additional credit of approximately ZAR 700 million (US$ 82.46 million) up to a facility limit of ZAR 1.55 billion under the existing facility for Atlatsa to finance its 51% pro rata share of expansion plans at Bokoni Mine (the “Debt Facility”).

The Debt Facility will be available to Atlatsa for seven years terminating on 31 December 2020 and will attract a variable interest rate, with a reduced interest charge during the initial debt profile term between 2013 – 2015 (comprising the capital intensive phase of the growth operations at Bokoni Mine) and escalating at an increased rate depending on the amount owing by Atlatsa under the Debt Facility over the funding period as set out in the interest rate table below:

The weighted average effective interest rate of the Debt Facility is estimated to be 2% per annum, thereby reducing Atlatsa’s expected cost of debt by 85% from approximately 13% to approximately 2% through to 2020.

There will be no fixed repayment terms for the Debt Facility through to 31 December 2018. However, Atlatsa will be required to fully repay the Debt Facility to Anglo American Platinum by 31 December, 2020. There will be no penalty for early repayment. Atlatsa will be required to reduce the Debt Facility owing to Anglo American Platinum to an outstanding balance (including capitalised interest) of:

I.     no more than ZAR 1 billion (US$ 117.8 million) as at 31 December 2018;

II.     no more than ZAR 500 million (US$ 58.90 million) as at 31 December 2019; and

III.     zero as at 31 December 2020.

Atlatsa will be obliged to utilise 90% of its attributable share of free cash flows generated from Bokoni Mine operations to service the Debt Facility and 10% of such free cash flow will be available as a “trickle dividend” in favour of Atlatsa. Atlatsa will not be required to effect any mandatory refinancing of the Debt Facility during the debt term through to 2020.

4.3 Unwinding the “B” preference share structure

The parties will unwind the “B” preference share structure in Atlatsa, such that Atlatsa will have only one class of common shares going forward.

Anglo American Platinum will subsequently sell its 115.8 million common shares in Atlatsa, arising from the unwind of the “B” preference shares, to Atlatsa Holdings for ZAR 463 million (US$ 54.54 million) through a vendor finance loan (the “Vendor Finance Facility”). Pursuant to such sale, Atlatsa Holdings will increase its shareholding in Atlatsa from 51% (current) to 62%, thereby creating additional equity financing flexibility for Atlatsa to raise additional financing through equity issuances and still maintain a 51% BEE majority shareholding in the company if required.

There are no fixed repayment terms for the Vendor Finance Facility through to 31 December, 2018. However, Atlatsa Holdings will be required to fully repay the Vendor Finance Facility to Anglo American Platinum by 31 December, 2020. There will be no penalty for early repayment. Atlatsa Holdings will be required to reduce the Vendor Finance Facility owing to Anglo American Platinum to an outstanding balance (including capitalised interest) of:

I.     no more than ZAR 232 million (US$ 27.33 million) as at 31 December 2018;

II.     no more than ZAR 116 million (US$ 13.66 million) as at 31 December 2019; and

III.     zero as at 31 December 2020.

Atlatsa Holdings will provide security to Anglo American Platinum in relation to the Vendor Finance Facility by way of a pledge and cession of its entire shareholding in Atlatsa, which shares remain subject to a lock-in arrangement through to 2020. Should Atlatsa Holdings be unable to meet its minimum repayment commitments in terms of the Vendor Finance Facility repayment obligations between 2018 to 2020, Atlatsa will have a discretionary right, with no obligation, to step in and remedy such obligation in order to protect its BEE shareholding status, subject to commercial terms being agreed between Atlatsa Holdings and Atlatsa for that purpose.

Subsequent to the implementation of the Revised Restructure Plan Atlatsa’s fully diluted shares in issue will increase to 555 million shares outstanding, with the following resultant shareholding:

4.4 Other agreements

The Bokoni Group will extend its existing concentrate purchase agreement with Anglo American Platinum on the same terms and conditions for a period of seven years, terminating on 31 December 2020.

Atlatsa will retain its existing option to acquire an ownership interest in Anglo American Platinum’s Polokwane smelter complex on terms agreed between Rustenburg Platinum Mine and Atlatsa.

5. Conditions precedent

The implementation of the Revised Restructure Plan will be subject, inter alia, to the fulfillment or, where appropriate, waiver of the following conditions precedent:

• Approval by the shareholders of Atlatsa;
• All of the agreements constituting the Revised Restructuring Plan becoming unconditional;
• To the extent required, unconditional approval by the Competition Authorities of South Africa;
• To the extent required, unconditional approval by the South African Reserve Bank; and
• Approval of the Revised Restructure Plan by the relevant regulatory authorities including the TSX Venture Exchange, JSE Limited, NYSE-MKT, the South African Department of Mineral Resources and ministerial approval of the transfer of mineral rights.

6. Effective date of the Revised Restructure Plan

The Effective Date of the Revised Restructure Plan is subject to the fulfilment of the conditions precedent as set out above. Further information will be provided once the conditions have been fulfilled.

7. Pro forma Financial effects relating to the Revised Restructure Plan and renewal of cautionary announcement

Shareholders are advised that the financial effects of the Revised Restructure Plan are still being determined and may have a material effect on the price of Atlatsa securities. Accordingly, shareholders are advised to continue exercising caution when dealing in Atlatsa securities until a further announcement is made. A further announcement will be released on the Securities Exchange News Service, filed on SEDAR and published in the South African press as soon as the financial effects have been finalised.

8. Categorisation in terms of JSE Listings Requirements

The Asset Sale constitutes a category 1 disposal to a related party under the provisions of section 9.5(b) read with section 10 of the Listings Requirements of the JSE and the subscription of shares by Anglo American Platinum constitutes a specific issue of shares for cash under the provisions of section 5 of the Listings Requirements of the JSE.

9. Information circular to shareholders

An information circular containing full details of the Revised Restructure Plan and relevant agreements and incorporating a notice of general meeting of Atlatsa shareholders, will be posted to Atlatsa shareholders, in due course.

Cautionary and forward-looking information

This document contains “forward-looking statements” that were based on Atlatsa’s expectations, estimates and projections as of the dates as of which those statements were made, including statements relating to the Bokoni Group  revised restructure plan or operational performance. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “will”, “outlook”, “anticipate”, “project”, “target”, “believe”, “estimate”, “expect”, “intend”, “should” and similar expressions.

Atlatsa believes that such forward-looking statements are based on material factors and reasonable assumptions, including the following assumptions: the revised restructure plan completed in a timely manner; the Bokoni Mine will achieve production levels as set out in the new operating plan; contracted parties provide goods and/or services on the agreed timeframes; equipment necessary for construction and development is available as scheduled and does not incur unforeseen breakdowns; no material labour slowdowns or strikes are incurred; plant and equipment functions as specified; geological or financial parameters do not necessitate future mine plan changes; and no geological or technical problems occur.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These include but are not limited to:

• uncertainties related to the receipt of the necessary shareholder, stock exchange and regulatory approvals and satisfaction of other conditions to the completion of the revised restructure plan in a timely manner, if at all;
• uncertainties related to the completion of the revised restructure plan transactions in a timely manner;
• uncertainties related to expected production rates, timing of production and the cash and total costs of production and milling;
• operating and technical difficulties in connection with mining development activities;
• changes in general economic conditions, the financial markets and in the demand and market price for gold, copper and other minerals and commodities, such as diesel fuel, coal, petroleum coke, steel, concrete, electricity and other forms of energy, mining equipment, and fluctuations in exchange rates,
• particularly with respect to the value of the U.S. dollar, Canadian dollar and South African rand;
• changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates; environmental issues and liabilities associated with mining including processing and stock piling ore;
• geopolitical uncertainty and political and economic instability in countries which we operate; and
• labour strikes, work stoppages, or other interruptions to, or difficulties in, the employment of labour in markets in which we operate mines, or environmental hazards, industrial accidents or other events or occurrences, including third party interference that interrupt the production of minerals in our mines.

For further information on Atlatsa, investors should review the Company’s annual Form 20-F filing with the United States Securities and Exchange Commission www.sec.gov and annual information form for the year ended December 31, 2012 and other disclosure documents that are available on SEDAR at www.sedar.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The NYSE Amex has neither approved nor disapproved the contents of this press release.

Image Sensing (ISNS) Announces Integration Partnership With Exacq Technologies

SAINT PAUL, Minn., April 9, 2013 (GLOBE NEWSWIRE) — Image Sensing Systems, Inc. (ISS) (Nasdaq:ISNS) is pleased to announce the integration of Exacq Technologies’ exacqVision video management system (VMS) with CitySync License Plate Recognition (LPR) software.

Users can now utilize CitySync’s industry leading LPR solution directly from the exacqVision client. License plates are scanned using CitySync’s line of specially configured IP cameras and the CitySync software running on a third party computer or directly on select exacqVision servers. License plate information is converted to serial data which can be searched for using the exacqVision client.

“We are excited to announce this partnership with Exacq Technologies,” said Kris Tufto, CEO of Image Sensing Systems. “We are certain that this partnership will broaden and further enhance our constantly growing LPR footprint and in addition bolster our efforts to provide users precise and accurate information to make more confident and proactive decisions.”

CitySync License Plate Recognition software is the fastest, most accurate automated license plate recognition (ALPR) engine in the world. This software assists the law enforcement, security and parking sectors by reading vehicle license plates, checking them against computer databases and then storing the data in a sophisticated back-office system called Jet-BOF.

“Integrating with CitySync provides our customers and end users with a powerful and easy-to-use solution to record license plate data,” notes Dave Underwood, President, Exacq Technologies. “The partnership between our two companies will provide a highly effective tool that combines both video and data evidence from the same user interface.”

Exacq Technologies will be showcasing the CitySync License Plate Recognition software integration during the upcoming ISC West conference and exhibition in Las Vegas, Nevada, April 10-12 at the Sands Convention Center.

About Image Sensing Systems, Inc.

Image Sensing Systems, Inc. is a provider of above ground detection and information management solutions for the Intelligent Transportation Systems (ITS) sector and adjacent markets including security, police and parking. We have sold more than 135,000 units of our industry leading Autoscope® machine-vision, RTMS® radar and CitySync automatic license plate recognition (ALPR) products in over 60 countries worldwide. The depth of our experience coupled with the breadth of our product portfolio uniquely positions us to provide powerful hybrid technology solutions and to exploit the convergence of the traffic, security and environmental management markets. We are headquartered in St. Paul, Minnesota. Visit us on the web at imagesensing.com.

About Exacq

Exacq Technologies (www.exacq.com) designs and manufactures the cross-platform, open-architecture exacqVision video management system (VMS) used in the physical security industry for IP video surveillance. exacqVision is available on factory-installed hybrid and IP camera servers or on commercial off-the-shelf servers. It can also be installed directly on compatible IP cameras, eliminating the need for a separate server. Video from exacqVision servers can be accessed with the free, cross-platform (Windows/Linux/Mac) client, most web browsers and via the free exacq Mobile app available for iPhone, iPad and Android devices. Exacq’s products are available throughout the world via authorized resellers and distributors.

CONTACT: Dan Skites, VP of Sales and Marketing
         Image Sensing Systems, Inc.
         Phone: 651-603-7700

Former Applebee’s President and CEO to Open 10 Pie Five Pizza Co. (PZZI) Locations

Restaurant Veteran Dave Goebel Joins Growing List of Prominent Pie Five Franchisees

THE COLONY, Texas, April 9, 2013 (GLOBE NEWSWIRE) — The Kansas City area will soon welcome its first Pie Five Pizza Co. restaurant in a 10-unit franchise agreement with former Applebee’s President and Chief Executive Officer Dave Goebel.

Goebel, a seasoned restaurant veteran who served as an executive at Applebee’s for seven years, will join forces with his sons Kerry and Kevin to bring Pie Five to the Kansas City area.

“We looked very carefully at several fast-casual pizza concepts before making our decision,” Goebel said. “Pie Five already has the franchise infrastructure and support system in place and this is our opportunity to get in on the ground floor of a concept that is rapidly expanding throughout the nation.”

Goebel was also impressed with the company’s industry and franchising experience, strong leadership team and approach to creating custom pizzas with the freshest ingredients, baked to order and ready to enjoy in just five minutes.

“Once we met the Pie Five leadership team, we were sold. They bring a wealth of restaurant experience from world-class concepts,” Goebel said. “I’ve been in this industry a long time, and I know a great brand when I see one. And Pie Five is not just great, it’s revolutionary.”

Goebel started in the restaurant industry almost 40 years ago after earning his undergraduate degree from University of Notre Dame and while working on his graduate degree from Ohio State University. He has held high level executive positions at well-known chains, including vice president of operations at Ground Round and chief operating officer and partner at Boston Market. Today he also sits on the Board of Directors for Jack in the Box, Inc.

“I fell in love with the restaurant business at an early age,” he added. “I love the fast pace and interaction with guests. I also love that the industry is always changing and evolving. Pie Five is a game changer in the fast-casual space.”

Goebel also owns Prime Catering, and operates Goodcents Deli Fresh Subs and Y-Leave Café locations as a franchisee in Kansas City. Goebel will open his first Pie Five location in Kansas City. The city was recently ranked number ten on Travel & Leisure’s “Best Cities for Pizza.”

With the addition of Goebel, Pie Five has signed development agreements in the last six months for 38 locations that will also take the chain to Utah, North Carolina and Florida.

“We are thrilled to welcome Dave, Kerry and Kevin to the Pie Five team,” said Randy Gier, CEO of Pie Five. “Dave and our growing franchise network bring a multitude of experience and pedigree to Pie Five. As we build and operate corporate locations alongside our franchisees, we are poised to become one of the top brands in the restaurant industry.”

Since the original Pie Five restaurant opened in Fort Worth, Texas, in 2011, the concept has been named a 2012 Hot Concept of the Year award winner by Nation’s Restaurant News and recognized by Forbes as one of the 10 hot new chains.

About Pie Five Pizza Co.:

Pie Five is a subsidiary of Pizza Inn Holdings, Inc. headquartered in the Dallas suburb of The Colony, Texas. Pizza Inn Holdings, Inc. is an owner, franchisor and supplier of a system of restaurants operating domestically and internationally. Pie Five Pizza Co. is a fast-casual concept offering individual pizzas made to order and cooked in less than five minutes. Founded in 1958, publicly traded Pizza Inn Holdings, Inc. (Nasdaq:PZZI) franchises approximately 300 restaurants and directly owns and operates 13 restaurants. For more information, please visit www.piefivepizza.com.

CONTACT: Media Contact:
         Brooke Ezell
         BizCom Associates
         469-275-4921
         Brooke@Bizcompr.com

Unilife (UNIS) Signs Long-Term Customization and Commercial Supply Agreement

Long-Term Customization and Commercial Supply Agreement for EZMix Dual Chamber Syringe

15-Year Contract Expected to Generate up to $110 Million, with Revenue Starting Immediately Unilife to Receive a Royalty of Net Drug Sales in Exchange for Exclusivity Rights

YORK, Pa., April 9, 2013 /PRNewswire/ — Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced the signing of a Customization and Commercial Supply Agreement with a U.S. pharmaceutical company (the “Customer”) for the EZMix^™ dual-chamber syringe.

(Photo:  http://photos.prnewswire.com/prnh/20130409/NY91030 )

Unilife will supply the Customer with a customized device from its EZMix platform of dual-chamber delivery systems (“EZMix” or the “device”) for use with a lyophilized drug (the “Drug”) that requires mixing at the time of injection. The Drug, which is a proprietary version of an approved therapy, is entering late-stage clinical development with the Customer planning an accelerated pathway to U.S. regulatory approval.

Unilife expects to generate up to $110 million in revenue during the 15-year agreement based upon a customization and production scale-up program, commercial device sales and a royalty of net drug sales. Unilife will immediately begin to generate revenues under the program.

The Customer will pay Unilife approximately $3 million over a 12 to 24-month period for the customization and supply of prefilled EZMix devices for scheduled activities including human clinical drug trials and compatibility testing. Unilife will receive an additional $3 million from the Customer to fund the production scale-up of high-volume assembly equipment to manufacture the customized device at commercial volumes.

In exchange for the Customer securing worldwide exclusivity to EZMix for its target drug, Unilife will receive royalty payments on net annual commercial revenue of the Drug. These royalty payments are expected to represent approximately a third of the $110 million in cumulative revenues generated by Unilife during the contract period. The agreement includes a guaranteed minimum annual royalty payment that the Customer must provide to Unilife in order to maintain EZMix exclusivity for the target drug.

For commercial purposes and due to confidentiality provisions in the agreement, additional terms of the contract and the identity of the Customer are to remain confidential at this time.

Comments by Alan Shortall, CEO of Unilife

“As the world’s only dual-chamber syringe with intuitive, ventless, orientation-free mixing and automatic needle retraction, EZMix is a game-changing technology for the delivery of liquid-liquid or liquid-dry drug combination therapies. Compared to conventional technologies which can take between five and a dozen complex steps to mix together the drug and diluent combination, EZMix can essentially achieve the same outcome with one easy, single-handed action. That makes EZMix an enabling technology for combination therapies targeted for use by healthcare workers or self-injecting patients,” Mr. Shortall said.

“More than ten pharmaceutical companies are now pursuing EZMix in recognition of how it can enable or enhance the clinical development and lifecycle management of their injectable therapies. Given the significant competitive advantages of EZMix, many of these pharmaceutical companies are requesting worldwide exclusivity for the device. In this case, we will receive a royalty of the Drug’s net commercial sales so that the customer can maintain exclusive access to EZMix for use with its target drug.

“This agreement highlights the multitude of ways in which we can generate significant revenue not only from the customization, sale and exclusive use of our devices, but also by receiving a royalty from the commercial revenue of the injectable therapies they will deliver and differentiate. Many of the agreements that we are negotiating with various pharmaceutical companies are expected to include a combination of these sources of revenue,” Mr. Shortall concluded.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

About EZMix™ Syringes

EZMix is an innovative and highly differentiated platform of dual-chamber syringes that meet the needs of lyophilized, powder filled or liquid-liquid drug combinations. Proprietary features include orientation-free, ventless mixing to minimize drug loss and maintain sterility until time of injection, and the automatic, user-controlled retraction of the needle upon full dose delivery to virtually eliminate the risk of needlestick injuries. EZMix dual-chamber syringes are designed for intuitive use by healthcare workers or patients, with minimal steps required for reconstitution and injection of the therapy. EZMix syringes feature USP compliant materials in the drug fluid path and are supplied in a standard packaging format for integration into standard fill-finish systems. Device variants include the EZMix syringe with a staked retractable needle and the EZMix Select with attachable retractable needles. Multiple customization options are available. Pharmaceutical companies seeking additional information on EZMix are asked to contact Unilife.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

GeoGlobal (GGR) Announces Sale of Certain Indian Assets

CALGARY, ALBERTA–(Marketwired – April 9, 2013) – GeoGlobal Resources Inc. (“GeoGlobal” or the “Company”) (NYSE MKT:GGR) announced today that it has entered into a share purchase agreement with Sarus Energy Ltd. (“Sarus”) pursuant to which Sarus will acquire 100% of the issued and outstanding shares of a wholly owned subsidiary of the Company, GeoGlobal Exploration (Barbados) Inc. (“GEB”), in a two-part transaction.

Included in the transaction is the Company’s 14% – 20% participating interest (“PI”) in the CB-ON/2 PSC (“Tarapur“), which includes: the Tarapur Mining Lease and the Tarapur Ring Fenced PSC; a 10% PI in CB-ONN-2003/2 (“Ankleshwar“); and a 10% PI in CB-ONN-2002/3 (“Sanand/Miroli“), (collectively referred to as the “Cambay Assets”).

On the first closing date, Sarus will acquire 49% of the issued and outstanding shares of GEB for US$2,000,000. The first part of the transaction is expected to close on April 12, 2013.

On the second closing date, Sarus will acquire the remaining 51% of the shares of GEB for US$14,000,000. The second closing is subject to certain terms, conditions and consents, including the approval of the Government of India.

About GeoGlobal

GeoGlobal Resources Inc., headquartered in Calgary, Alberta, Canada, is a U.S. publicly traded oil and gas company, which, through its subsidiaries, is engaged in the pursuit of petroleum and natural gas in high potential exploration targets through exploration and development in India, Israel and Colombia.

Cautionary Statement For Purposes Of The “Safe Harbor” Provisions Of The Private Securities Litigation Reform Act Of 1995.

This press release contains statements which constitute forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Such statements contain words such as “believes,” “estimates,” “expects,” “intends,” “plans,” “projects,” “may,” “will,” “might,” “should,” “could,” “would,” “seeks,” “pursues,” and “anticipates” or the negative or other variation of these or similar words, or may include discussions of strategy or risks and uncertainties. These statements include statements regarding the plans, intentions, beliefs and current expectations of GeoGlobal Resources Inc., its directors, or its officers with respect to the oil and gas exploration, development and drilling and spudding activities being conducted and intended to be conducted and the outcome of those activities on the exploration blocks in which the Company has an interest. Any forward-looking information in or referred to by this press release is current only as of the date of publication, and GeoGlobal disclaims any obligation to update this information, except as required by law. The company updates forward-looking information related to operations, production and capital spending on a quarterly basis and updates reserves, if any, on an annual basis.

We caution you that various risk factors accompany our forward-looking statements and are described, among other places, under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. These risk factors could cause our operating results, financial condition and ability to fulfill our plans to differ materially from those expressed in any forward-looking statements made in this press release and could adversely affect our financial condition and our ability to pursue our business strategy and plans. If our plans fail to materialize, your investment will be in jeopardy.

An investment in shares of our common stock involves a high degree of risk. Our periodic reports, which we file with the Securities and Exchange Commission and Canadian provincial authorities may be viewed at http://www.sec.gov and www.sedar.com.

Contact Information:
GeoGlobal Resources Inc.
+1-403-777-9250
info@geoglobal.com
www.geoglobal.com

The Equicom Group
Nick Hurst
+1-403-218-2835
nhurst@tmxequicom.com

Medical Action (MDCI) Reports Third Quarter Fiscal 2013 Results

BRENTWOOD, N.Y., Feb. 11, 2013 (GLOBE NEWSWIRE) — Medical Action Industries Inc. (Nasdaq:MDCI), a leading supplier of medical and surgical disposable products, today reported financial results for the third quarter ended December 31, 2012, including quarterly net sales of $109.4 million and gross profit of $19.1 million (the highest in Company history) or 17.5% of net sales. The Company generated non-GAAP net income (before a goodwill impairment charge and certain professional fees) of $1.6 million⁽¹⁾or $0.10⁽¹⁾ per diluted share and EBITDA, as adjusted, of $6.1 million⁽²⁾. These gross profit, non-GAAP net income and EBITDA, as adjusted results represent significant increases versus the comparable non-GAAP results for the same period of fiscal 2012. On a GAAP basis, the Company reported a net loss of $55.5 million or $3.39 per diluted share, principally related to the impairment of goodwill of $56.8 million, net of income tax benefit, determined in connection with the Company’s annual goodwill impairment test as of December 31, 2012.

For the nine months ended December 31, 2012, the Company reported net sales of $333.7 million, gross profit of $53.5 million or 16.0% of net sales, non-GAAP net income of $2.0 million⁽¹⁾ or $0.12⁽¹⁾ per diluted share and EBITDA, as adjusted, of $14.1 million⁽²⁾, all of which exceeded the comparable non-GAAP results for the first nine months of fiscal 2012. On a GAAP basis, the Company reported a net loss of $55.6 million or $3.39 per diluted share. Additionally, since March 31, 2012, the Company has reduced the balance outstanding under its debt facilities by $21.3 million.

Paul D. Meringolo, Chief Executive Officer and President said, “We have made significant improvements in our gross profit culminating with the $19.1 million reported during the third quarter, which is the highest quarterly amount in the Company’s thirty-six year history. This improvement in gross profit is the result of management’s cost savings initiatives, elimination of unprofitable sales, as well as a reduction in raw material costs. Since June 2012, when the Company was realigned into strategic business units, management’s focus on targeted markets has improved considerably and the action plans centered on improving profit and containing costs have yielded the year over year and sequential gross profit improvements we are reporting today. We have been able to make these impressive strides by improving upon our internal operations and management effectiveness without compromising our focus on delivering exceptional service and value to our customers. We still have challenges and opportunities ahead of us and I am extremely pleased at the success we have had in the last several months as we have refocused the Company. Finally, I am excited about the opportunity to work with our interim Chief Operating Officer, Paul Chapman, on continuing to drive improvements in profit and cost containment.”

Quarter Results

Net sales for the third quarter were $109.4 million, down $3.6 million or 3.2% from net sales of $113.0 million for the third quarter of last year. This modest decrease results in part from management’s efforts to focus on profitable business and to decrease or eliminate unprofitable or non-core sales. The reported gross profit of $19.1 million, or 17.5% of net sales, represents a record result for the Company while the gross margin percentage is the highest in two years. By comparison, gross profit in the prior year period amounted to $17.1 million or 15.2% of net sales. This improvement in gross profit is the result of management’s cost savings initiatives, elimination of unprofitable sales, as well as a reduction in raw material costs.

On a GAAP basis, the Company reported a net loss of $55.5 million or $3.39 per diluted share, compared to reported net income of $1.8 million or $0.11 per diluted share for the same period of fiscal 2012. The results for the third quarter were impacted by a non-recurring, non-cash goodwill impairment charge of $78.6 million and $0.5 million of professional fees related to our renegotiated credit agreement. The after-tax impact of the goodwill impairment charge was $56.8 million and $0.3 million for the professional fees. The goodwill impairment was determined as part of the Company’s regular annual impairment test and had no effect on the Company’s cash position. The results for the same period of fiscal 2012 benefitted from a bonus accrual reversal of $1.8 million, net of applicable taxes, related to a reduction in the Company’s bonus accrual which was precipitated by the failure to meet certain operational performance objectives.

On a non-GAAP basis, the Company generated non-GAAP net income (before a goodwill impairment charge and certain professional fees) of $1.6 million⁽¹⁾or $0.10⁽¹⁾ per diluted share for the third quarter compared to a non-GAAP net income (before bonus accrual reversal) of less than $0.1 million⁽¹⁾ or $0.00⁽¹⁾ per diluted share for the same period of fiscal 2012. EBITDA, as adjusted, for the third quarter was $6.1 million⁽²⁾ compared to $3.8 million⁽²⁾ for the same period of fiscal 2012.

Year-to-Date Results

Net sales for the nine months ended December 31, 2012 were $333.7 million, an increase of $4.6 million or 1.4% from net sales of $329.1 million for the first nine months of fiscal 2012. Our gross profit of $53.5 million or 16.0% of net sales has improved compared to the gross profit of $50.8 million or 15.4% for the first nine months of fiscal 2012. This improvement in gross profit is the result of management’s cost savings initiatives, elimination of unprofitable sales, as well as a reduction in raw material costs.

On a GAAP basis, the Company reported a net loss of $55.6 million or $3.39 per diluted share, compared to reported net income of $2.6 million or $0.16 per diluted share for the same period of fiscal 2012. The results for the nine months ended December 31, 2012 were impacted by the previously described goodwill impairment charge of $78.6 million ($56.8 million after income tax benefit) and $1.1 million of professional fees ($0.7 million after income tax benefit) related to our renegotiated credit agreement. The results for the same period of fiscal 2012 benefitted from the aforementioned bonus accrual reduction of $1.8 million, net of applicable taxes, and an extraordinary gain of $0.4 million, net of applicable taxes, resulting from an insurance settlement associated with damaged inventories.

On a non-GAAP basis, the Company generated non-GAAP net income (before a goodwill impairment charge and certain professional fees) of $2.0 million⁽¹⁾or $0.12⁽¹⁾ per diluted share for the nine months ended December 31, 2012 compared to non-GAAP net income (before bonus accrual reversal and extraordinary gain) of $0.4 million⁽¹⁾ or $0.03⁽¹⁾ per diluted share for the first nine months of fiscal 2012.  EBITDA, as adjusted, for the nine months ended December 31, 2012 was $14.1 million⁽²⁾ compared to $12.2 million⁽²⁾ for the first nine months of fiscal 2012.

Liquidity and Capital Resources

The balance of cash and cash equivalents was $0.2 million at December 31, 2012, down $5.2 million from March 31, 2012. For the nine months ended December 31, 2012, the Company reported cash generated by operating activities of $17.5 million compared to cash generated by operating activities of $3.6 million for the first nine months of fiscal 2012. The Company manages cash and cash equivalent balances to minimize the amounts outstanding under its revolving credit facility in an effort to reduce borrowing costs. As of December 31, 2012, the Company had $10.7 million available for additional borrowing under its revolving credit facility.

The Company’s outstanding debt on its credit facility was $54.4 million at December 31, 2012, down $21.3 million from March 31, 2012. The credit facility consists of; (i) a term loan with $49.0 million outstanding at December 31, 2012 and (ii) a revolving credit facility with $5.3 million outstanding at December 31, 2012. As of December 31, 2012, the Company is in compliance with all covenants and financial ratios applicable under our credit facility. Furthermore, we believe that the anticipated future cash flow from operations, coupled with our cash on hand and available funds under our revolving credit facility will be sufficient to meet working capital requirements.

Investors Conference Call

Medical Action invites its stockholders and other interested parties to attend its conference call at 10:00 a.m. (ET) on February 11, 2013. You may listen to the conference call by calling (888) 868-9080 (domestic) or (973) 935-8511 (international); conference ID #97614083. The conference call will be simultaneously web cast on our website: www.medical-action.com. The complete call and discussion will be available for replay on our website beginning at 1:00 p.m. (ET) on February 11, 2013.

About Medical Action Industries Inc.

Medical Action Industries Inc. (Nasdaq:MDCI), is a diversified manufacturer and distributor of disposable medical devices and a leader in many of the markets where it competes. Its products are marketed primarily to acute care facilities in domestic and certain international markets. The Company has expanded its target market to include physician, dental and veterinary offices, out-patient surgery centers, long-term care facilities and laboratories. Medical Action’s products are marketed nationally by its direct sales personnel and extensive network of healthcare distributors. The Company has preferred vendor agreements with national and regional distributors, as well as sole and multi-source agreements with group purchasing organizations. Medical Action’s common stock trades on the NASDAQ Global Select Market under the symbol MDCI and is included in the Russell Microcap^® Index.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives for management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All forward-looking statements included in this news release are made as of the date hereof and are based on information available to us as of such date. The Company assumes no obligation to update any forward-looking statement. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology. Although the Company believes that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including manufacturing inefficiencies, termination or interruption of relationships with our suppliers, potential delays in obtaining regulatory approvals, product recalls, product liability claims, our inability to successfully manage growth through acquisitions, our failure to comply with governing regulations, risks of international procurement of raw materials and finished goods, market acceptance of our products, market price of our Common Stock, foreign currency fluctuations, resin volatility and other factors referred to in our press releases and reports filed with the Securities and Exchange Commission (the “SEC”). Please see the Company’s filings with the SEC, including, without limitation, the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Qs, which identify specific factors that would cause actual results or events to differ materially from those described in the forward-looking statements.

Footnotes

The press release includes the use of non-GAAP financial measures that are not prepared in accordance with U.S. generally accepted accounting principles and that exclude the effects of a goodwill impairment charge recognized during the three months ended December 31, 2012 and professional fees related to our renegotiated credit agreement incurred during the three and nine months ended December 31, 2012 as well as a bonus accrual reversal and extraordinary gain reported during the comparable prior periods of fiscal 2012. These non-GAAP financial measures should not be considered a substitute for measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures have been used in this press release because management believes they are useful to investors by providing greater transparency to Medical Action’s operating performance.

(1) Reconciliation of net income (loss) to non-GAAP net income and non-GAAP earnings per share

(2) Reconciliation of net income (loss) to EBITDA and EBITDA, as adjusted

EBITDA is defined as earnings (loss) before interest, income taxes, depreciation and amortization.  EBITDA is a non-GAAP financial measure.

EBITDA, as adjusted represents EBITDA as defined above adjusted for a goodwill impairment charge recognized during the three months ended December 31, 2012, professional fees related to our renegotiated credit agreement recognized during the three and nine months ended December 31, 2012, a bonus accrual reversal and extraordinary gain recognized during the three and nine months ended December 31, 2011 and stock-based compensation.  Stock-based compensation represents compensation expenses associated with stock options and restricted stock.

Management believes EBITDA and EBITDA, as adjusted, to be meaningful indicators of our performance that provides useful information to investors regarding our financial condition and results of operations. Presentations of EBITDA and EBITDA, as adjusted, are non-GAAP financial measures commonly used by financial analysts and our lenders to measure operating performance.  While management considers EBITDA and EBITDA, as adjusted, to be important measures of comparative operating performance, they should be considered in addition to, but not as a substitute for, net income and other measures of financial performance reported in accordance with GAAP.  EBITDA and EBITDA, as adjusted do not reflect cash available to fund cash requirements.  Not all companies calculate EBITDA or EBITDA, as adjusted in the same manner and the measure as presented may not be comparable to similarly-titled measures presented by other companies.

CONTACT: John Sheffield
         Executive Vice President and Chief Financial Officer
         MEDICAL ACTION INDUSTRIES INC.
         (631) 231-4600

Wave (WAVX) Announces FIPS-Mode Support for BitLocker Management

LEE, MA — (Marketwired) — 04/08/13 — Wave Systems Corp. (NASDAQ: WAVX), the Trusted Computing Company, is offering enhanced FIPS-mode management capabilities for enterprises seeking greater control and easier management of Microsoft® BitLocker™, the full-disk encryption feature on select versions of Vista, Windows 7 and Windows 8. FIPS refers to the Federal Information Processing Standard 140, which is required for all cryptography procured and used by the U.S. government and Department of Defense.

“BitLocker™ has become increasingly popular as a more secure means to encrypt data, but many organizations lack the expertise to fully leverage BitLocker™ and the advanced FIPS settings built in,” said Brian Berger, Executive Vice President and CMO for Wave Systems. “A FIPS-compliant BitLocker™ deployment is easy with Wave; users can set policies with a click of a button, and monitor security from a single console — dramatically simplifying the roll out in mixed OS environments by eliminating the need for specialized knowledge or costly systems.”

Many government agencies, supply chain, and commercial organizations that adhere to government’s regulations require that BitLocker™ be configured with FIPS enabled. Technically that means only the strongest encryption algorithms are available and some of the simpler recovery procedures cannot be used. FIPS mode is also becoming a requirement in industries with particular security or privacy concerns such as banking, automotive and healthcare.

Administration Beyond MBAM
While the security and compliance benefits of BitLocker™ are evident to a growing number of organizations — notably within government — the lack of a central management solution has presented a roadblock to adoption. For basic management of BitLocker™ deployments, MBAM (Microsoft® BitLocker™ Administration & Monitoring) provides a help desk and reporting interface (available to those who purchase seat licenses for Microsoft Desktop Optimization Pack). Wave management solutions go beyond help desk and reporting by giving administrators the ability to remotely manage clients, to enable or disable encryption and to check encryption status. For environments where security is paramount, Wave provides a simple interface to create a BitLocker™ startup token that can be used in conjunction with the Trusted Platform Module (TPM) to implement a split-key deployment. In such a deployment a data can only be decrypted after the user has inserted the startup token and then unlocked the TPM with a PIN.

Wave for BitLocker™ Management organizes the core Microsoft capabilities into a simple and intuitive administrative application for setting up and maintaining BitLocker™ clients. Wave eliminates the cost and complexity associated with creating custom scripts and Active Directory schema extensions and its console makes it easy to initialize, configure and administer deployment of BitLocker™ clients. Time and resource-strapped IT departments have a powerful tool for:

• Remote discovery and activation of BitLocker™ client machines
• Zero touch deployment and management of the TPM
• Assignment of users and associated policies (using existing Microsoft Active Directory frameworks)
• Secure recovery of passwords (with audit recording of their usage)
• Monitoring of all BitLocker™ events — from activation and policy management, to user access/recovery and help desk functions.
• Security and compliance reporting — for a secure record of proof that data was protected in the event a PC is lost or stolen.

Single Console for BitLocker™ AND Trusted Computing
BitLocker™ offers even greater protection when used in conjunction with the TPM, which ships as a standard component on business-class PCs, laptops and Windows 8 mobile tablet devices. Transparent to the user, the TPM adds hardware protection for encryption keys and recovery passwords, extending BitLocker™ security to protect data and ensure that an organization’s PCs or devices have not been tampered with. On computers that have a TPM version 1.2, BitLocker™ uses the TPM to help ensure that data is accessible only if the computer’s boot components appear unaltered, and the encrypted disk is located in the original computer. When using Wave, the TPM is not reserved exclusively for BitLocker™. It can also be used for device identity, machine health and hardware protected user identities. Modern malware attacks are making these security capabilities increasingly essential.

Wave for BitLocker™ Management console allows remote management of the OPAL-compliant SEDs in all your devices (OPAL-1 as well OPAL-2, standards from the Trusted Computing Group). Wave Endpoint Monitor (WEM) complements the security of BitLocker and SEDs and provides digitally signed proof of the endpoint’s health. By continuously monitoring the state of the machine s, measurements generated by Wave leveraging the TPM chip, WEM is able to generate alerts if a local administrator or a piece of malicious code disables encryption, BIOS or changes to the master boot record (MBR).

To learn more about wave’s simple, cost-effective government solutions, including BitLocker, TPM and SED management, visit www.wave.com.

About Wave Systems
Wave Systems Corp. (NASDAQ: WAVX) reduces the complexity, cost and uncertainty of data protection by starting inside the device. Unlike other vendors who try to secure information by adding layers of software for security, Wave leverages the security capabilities built directly into endpoint computing platforms themselves. Wave has been a foremost expert on this growing trend, leading the way with first-to-market solutions and helping shape standards through its work as a board member for the Trusted Computing Group.

Safe Harbor for Forward-Looking Statements
This press release may contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company’s financing plans; (ii) trends affecting the company’s financial condition or results of operations; (iii) the company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Wave assumes no duty to and does not undertake to update forward-looking statements.

All brands are the property of their respective owners.

Company:
Wave Systems Corp.
Michael Wheeler
413-243-7026
mwheeler@wavesys.com

Investor Relations:
David Collins
Eric Lentini
212-924-9800

Dot Hill (HILL) Announces Quantum Will OEM Midrange Storage Systems

Quantum Executive to Present at Dot Hill Analyst Day April 8th

LONGMONT, Colo., April 8, 2013 (GLOBE NEWSWIRE) — Dot Hill Systems Corp. (Nasdaq:HILL), a leading provider of SAN storage solutions, has entered into an OEM agreement with Quantum Corp., a proven global expert in Big Data management and data protection. Under the terms of the agreement, Quantum will incorporate Dot Hill AssuredSAN™ 4000 series storage systems into its Big Data product line.

Quantum senior vice president, file system and archive product group, Janae Stow Lee, stated, “As we further expand our solutions offerings for helping customers meet their Big Data challenges, we continue to combine the power of our own technologies with those from partners, which already include a number of major industry players. Dot Hill’s solid, high-performance architecture provides high bandwidth and high transaction input/output for Big Data, and we’re pleased to add them to our list of key suppliers.”

“To drive revenue growth, Dot Hill launched a midrange line and actively pursues partners in select Vertical Markets, such as Quantum, a leader in our targeted Big Data and Media and Entertainment markets,” said Dot Hill Systems president and chief executive officer Dana Kammersgard. “We believe being chosen to be part of Quantum’s storage solutions validates our product performance and illustrates our strategy implementation.”

“The AssuredSAN 4000 series is one of two new midrange storage offerings,” said Jim Jonez, senior director of marketing, Dot Hill. “As a highly scalable, highly available SAN solution optimized for post-production workflow performance, it is the high performance choice for organizations running data-intensive applications.”

Providing a solid, high-performance storage architecture, Dot Hill AssuredSAN Fibre Channel arrays provide up to 384TB of high speed 8Gb Fibre Channel storage that can be shared by multiple users for maximum efficiency and increased workflow productivity. Designed with a powerful processor, Dot Hill AssuredSAN systems provide high performance for sequential workloads.

About Dot Hill

Leveraging its proprietary Assured family of storage solutions, Dot Hill solves many of today’s most challenging storage problems – helping IT to improve performance, increase availability, simplify operations, and reduce costs. Dot Hill’s solutions combine breakthrough software with the industry’s most flexible and extensive hardware platform and automated management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in China, Germany, India, Japan, Singapore, the United Kingdom, and the United States. For more information, visit us at www.dothill.com.

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Because such statements are subject to risks and uncertainties, actual results may differ from those expressed or implied by the statements. For a discussion of risks and uncertainties that Dot Hill may face, please consult the Forms 10-K and 10-Q most recently filed with the Securities and Exchange Commission by Dot Hill. Forward-looking statements speak only as of the date they were made and Dot Hill undertakes no obligation to update such statements to reflect changes in circumstances.

HILL-G

CONTACT: Lutz PR
         Steve Sturgeon
         858-472-5669
         steve@lutzpr.com

         Dot Hill Systems Public Relations
         Ruth Macdonald
         303-845-3364
         ruth.macdonald@dothill.com

         Dot Hill Systems Investor Relations
         Jodi Bochert
         303-845-3467
         investors@dothill.com

         LHA Investor Relations
         Kirsten Chapman
         415-433-3777
         dothill@lhai.com

OriGene to Acquire (SDIX)’s Life Science Business Assets

ROCKVILLE, Md., April 8, 2013 /PRNewswire/ — OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications with operations in the United States and China, announced that it has signed a definitive agreement to acquire all the assets of the Life Science business of SDIX™ (NASDAQ: SDIX), a leading provider of biotechnology-based products and services.

(Logo: http://photos.prnewswire.com/prnh/20130408/DC90285LOGO)

“We anticipate the combination of SDIX with OriGene will enhance our ability to continue to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications both in research and diagnostics fields.  SDIX’s over 20 years of antibody development and production expertise will complement OriGene’s existing high-throughput monoclonal antibody capacity to develop the highest quality antibodies such as UltraMAB™,” said Wei-Wu He, Ph.D., OriGene’s Chairman and Chief Executive Officer.  OriGene expects the acquisition of SDIX to:

• Enhance the capabilities of OriGene to provide the most comprehensive immunization strategies for antibody development using full-length mammalian produced protein and genetic immunization technologies to create the highest quality monoclonal antibodies available
• Expand antibody and IVD reagent product and services capabilities to create significant new commercial opportunities for our existing and new customers including producing UltraMAB™ for future diagnostic uses

This transaction will uniquely position OriGene as one of the leaders in antibody development and production to help our customers find the best solutions for their antibody and assay needs.  The acquisition is expected to be completed during the second quarter of 2013, subject to the approval of SDIX’s shareholders and other customary closing conditions.

About OriGene Technologies

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significant improvement over traditional antibodies in antibody specificity.  UltraMAB™ antibodies are validated by OriGene’s proprietary high density microarray technology for a wide variety of antibody applications.

For more information, visit www.origene.com.

BSD Medical (BSDM) Announces Exclusive Multi-Million Dollar Distribution Agreement

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has signed an exclusive, long-term, multi-million dollar distribution agreement with Terumo Europe NV, a wholly owned subsidiary of Terumo Corporation (Terumo), for the MicroThermX^® Microwave Ablation System (MicroThermX^®).

A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2012 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology. Embolization and ablation are “hand-in-hand” clinical procedures for the treatment of cancerous tumors and, when used together, enable a less invasive course of treatment. This agreement therefore creates an ideal product synergy with BSD’s MicroThermX^® product line and enables Terumo Europe NV to offer interventional oncologists a complete and compelling solution for the treatment of cancerous tumors.

Under the terms of the distribution agreement, Terumo Europe NV will have the exclusive right to market MicroThermX^® in 100 countries in Europe, Western Asia, and Northern Africa. The potential market size for MicroThermX^® in these countries is estimated to be in excess of $1 billion in annual sales. This agreement validates the large market opportunity for MicroThermX^® ablation products and is expected to drive market adoption for the MicroThermX^® as a leading ablation therapy system. Strategically, MicroThermX^® will benefit from Terumo Europe NV’s extensive market reach, focus on interventional oncology, and well-established relationships with key interventional oncology opinion leaders throughout Europe.

“Our distribution agreement with Terumo Europe NV is the result of a collaborative effort between BSD Medical and Terumo. Importantly, it represents one of the most significant milestones in BSD’s corporate history,” said Harold Wolcott, BSD President and CEO. “Revenues from our agreement with Terumo Europe NV should commence by the end of the third quarter of our fiscal year 2013 and are expected to make a substantial contribution to our overall revenue over the next few years. Longer term, we expect this agreement will make a strong contribution toward our objective of achieving profitability.”

About the MicroThermX^® Microwave Ablation System

The MicroThermX^® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX^® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX^® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX^® introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX^® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX^® System, which allows BSD to market the MicroThermX^® in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX^® to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical’s website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Gus D. Halas (HH) Appointed to the Board of Directors of Hooper Holmes

Hooper Holmes (NYSE MKT: HH) today announced that Gus D. Halas has been appointed to the Company’s Board of Directors, effective April 2, 2013.

“We are excited to have Gus join Hooper Holmes’ Board of Directors,” stated Ronald V. Aprahamian, Chairman of Hooper Holmes. “Gus has successfully implemented turnaround initiatives at a number of companies throughout his career. This experience will be a valuable addition to Hooper Holmes’ Board. I look forward to working with Gus to create long-term shareholder value.”

Mr. Halas is currently Chief Executive Officer and President of the Central Operating Companies at Central Garden & Pet Company (NASDAQ: CENT). In addition, Mr. Halas serves on the board of Triangle Petroleum (NYSE: TPLM) and is a senior advisor and partner of White Deer Energy, a Houston based private equity firm. From 2003 to 2009, Mr. Halas was Chairman, President and CEO of T3 Energy Services. He previously served as President and Chief Executive Officer of Clore Automotive and Marley Cooling Tower Company and held senior executive positions with a number of other companies including Ingersoll-Dresser Pump Company and Sulzer Industries.

Mr. Halas holds a BS in Physics and a BS in Economics from Virginia Polytechnic Institute.

About Hooper Holmes

Hooper Holmes is a leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. With a presence in hundreds of markets and a network of thousands of examiners, Hooper Holmes can arrange a medical exam anywhere in the U.S. and deliver the results to its customers.

Hooper Holmes has four service lines. Portamedic provides a wide range of medical exam services nationwide. Heritage Labs tests millions of samples annually and helps life insurers improve underwriting performance by better applying the predictive powers of today’s tests. Hooper Holmes Health & Wellness performs risk assessment and risk management services including biometric screenings, health risk assessments and onsite wellness coaching for wellness companies, disease management organizations, clinical research organizations and health plans. Hooper Holmes Services reduces the insurance sales cycle through integrated data collection, tele-interviewing and underwriting services.

Avino (ASM) Q1/March Production Report

VANCOUVER, BRITISH COLUMBIA — (Marketwired) — 04/05/13 — Avino Silver & Gold Mines Ltd. (TSX VENTURE:ASM)(NYSE MKT:ASM)(BERLIN:GV6)(FRANKFURT:GV6) (“Avino” or “the Company”) is pleased to announce the following Q1 and March 2013 production results from its San Gonzalo mine operation located on the Avino property near Durango, Mexico.

Production numbers from Q1 2013 compared to Q4 2012 are presented below:

----------------------------------------------------------------------
                                           Q4 2012   Q1 2013  % Change
----------------------------------------------------------------------
Total Mill Feed (dry tonnes)                19,539    19,723       0.9
----------------------------------------------------------------------
Average Daily Throughput (tpd)                 222       229       3.1
----------------------------------------------------------------------
Days of Operation                               88        86      (2.3)
----------------------------------------------------------------------
Feed Grade Silver (g/t)                        259       309      19.3   1
----------------------------------------------------------------------
Feed Grade Gold (g/t)                         1.04      1.29      24.0   2
----------------------------------------------------------------------
Bulk Concentrate (dry tonnes)                  538       568       5.6   3
----------------------------------------------------------------------
Bulk Concentrate Grade Silver (kg/t)          7.44      8.72      17.0   3
----------------------------------------------------------------------
Bulk Concentrate Grade Gold (g/t)             26.3      31.4      19.3
----------------------------------------------------------------------
Recovery Silver (%)                             79        81       2.5
----------------------------------------------------------------------
Recovery Gold (%)                               70        70         0
----------------------------------------------------------------------
Mill Availability (%)                         94.4      95.5       1.2
----------------------------------------------------------------------
Total Silver Produced (kg)                   4,000     4,960      24.1
----------------------------------------------------------------------
Total Gold Produced (g)                     14,161    17,875      26.2
----------------------------------------------------------------------
Total Silver Produced (oz) calculated      128,607   159,582      24.1
----------------------------------------------------------------------
Total Gold Produced (oz) calculated            455       574      26.2
----------------------------------------------------------------------
Total Silver Equivalent Produced (oz)      151,372   191,107      26.2   4
----------------------------------------------------------------------

Silver equivalent for January through March was calculated using a 55:1 ratio for silver to gold. For the months of October, November and December, a 50:1 ratio was used in the calculation. (The ratio was changed to reflect more current gold and silver prices.) Mill production figures have not been reconciled and are subject to adjustment with concentrate sales. Year-to-date and calculated figures may not add up due to rounding.

1.  Feed grade for silver during Q1 2013 increased by 19.3% over Q4 2012
2.  Feed grade for gold during Q1 2013 increased by 24% over Q4 2012
3.  Bulk concentrate grades for silver and gold increased by 17% and 19.3%
    respectively during Q1 2013 as compared to Q4 2012
4.  The above resulted in a 24.1% and 26.2% increase in silver and gold
    production respectively.

Production numbers from March and the first six months at San Gonzalo, as well as 2013 yearly totals are reported as follows:

---------------------------------------------------------------------------
                                          Oct       Nov       Dec       Jan
                                         2012      2012      2012      2013
---------------------------------------------------------------------------
Total Mill Feed (dry tonnes)            6,647     6,528     6,364     6,392
---------------------------------------------------------------------------
Average Daily Throughput (tpd)            214       218       235       228
---------------------------------------------------------------------------
Days of Operation                          31        30        27        28
---------------------------------------------------------------------------
Feed Grade Silver (g/t)                   233       256       287       315
---------------------------------------------------------------------------
Feed Grade Gold (g/t)                    0.93      0.99      1.19      1.27
---------------------------------------------------------------------------
Bulk Concentrate (dry tonnes)             180       177       181       197
---------------------------------------------------------------------------
Bulk Concentrate Grade Silver
 (kg/t)                                  7.04      7.37      7.90      8.32
---------------------------------------------------------------------------
Bulk Concentrate Grade Gold (g/t)        25.0      25.4      28.6      29.1
---------------------------------------------------------------------------
Recovery Silver (%)                        82        78        78        81
---------------------------------------------------------------------------
Recovery Gold (%)                          72        69        68        70
---------------------------------------------------------------------------
Mill Availability (%)                    97.2      98.1      87.9      91.1
---------------------------------------------------------------------------
Total Silver Produced (kg)              1,265     1,302     1,433     1,638
---------------------------------------------------------------------------
Total Gold Produced (g)                 4,489     4,487     5,185     5,722
---------------------------------------------------------------------------
Total Silver Produced (oz)
 calculated                            40,671    41,870    46,066    52,779
---------------------------------------------------------------------------
Total Gold Produced (oz) calculated       144       144       167       184
---------------------------------------------------------------------------
Total Silver Equivalent Produced
 (oz)                                  47,888    49,083    54,401    62,781
---------------------------------------------------------------------------

---------------------------------------------------------------------------
                                          Feb     March   Monthly
                                         2013      2013  Change %    YTD SG
---------------------------------------------------------------------------
Total Mill Feed (dry tonnes)            6,418     6,913       7.7    19,723
---------------------------------------------------------------------------
Average Daily Throughput (tpd)            229       230       0.4     229(i)
---------------------------------------------------------------------------
Days of Operation                          28        30       7.1        86
---------------------------------------------------------------------------
Feed Grade Silver (g/t)                   306       307       0.3     309(i)
---------------------------------------------------------------------------
Feed Grade Gold (g/t)                    1.19      1.40      17.6    1.29(i)
---------------------------------------------------------------------------
Bulk Concentrate (dry tonnes)             166       206      24.0       569
---------------------------------------------------------------------------
Bulk Concentrate Grade Silver
 (kg/t)                                  9.43      8.52      (9.6)   8.72(i)
---------------------------------------------------------------------------
Bulk Concentrate Grade Gold (g/t)        30.4      34.5      13.5    31.4(i)
---------------------------------------------------------------------------
Recovery Silver (%)                        80        83       3.8      81(i)
---------------------------------------------------------------------------
Recovery Gold (%)                          66        73      10.6      70(i)
---------------------------------------------------------------------------
Mill Availability (%)                    99.0      96.7      (2.3)   95.5(i)
---------------------------------------------------------------------------
Total Silver Produced (kg)              1,565     1,758      12.3     4,961
---------------------------------------------------------------------------
Total Gold Produced (g)                 5,036     7,117      41.3    17,875
---------------------------------------------------------------------------
Total Silver Produced (oz)
 calculated                            50,315    56,513      12.3   159,607
---------------------------------------------------------------------------
Total Gold Produced (oz) calculated       162       229      41.3       575
---------------------------------------------------------------------------
Total Silver Equivalent Produced
 (oz)                                  59,228    69,098      16.7   191,107
---------------------------------------------------------------------------
(i)Year to date average

Silver equivalent for January through March was calculated using a 55:1 ratio for silver to gold. For the months of October, November and December, a 50:1 ratio was used in the calculation. (The ratio was changed to reflect more current gold and silver prices.) Mill production figures have not been reconciled and are subject to adjustment with concentrate sales. Year-to-date and calculated figures may not add up due to rounding.

March Highlights 

--  Total silver equivalent ounces in March increased by 16.7% over
    February.
--  The increase was due to the higher tonnage processed, improved silver
    recovery of 83%, and the better gold feed grade of 1.4 g/t.
--  Tonnage processed was higher than February because of 2 additional
    operational days.
--  Silver concentrate grade was slightly lower in March and resulted in
    more tonnage of concentrate produced. However, the gold grade in the
    concentrate increased due to the higher gold grade in the feed and the
    improved gold recovery.
--  During the month, two truckloads of concentrate were shipped and sold;
    the balance of the concentrate produced in March will be shipped in
    April.
--  Stockpiled inventory near the crushing facility increased to an
    estimated 13,674 from 12,610 tonnes in March.

Processing Facility Update

Activation of circuit 2 (see news release dated March 04, 2013) is well underway. The new 250 tpd circuit is expected to be tested in mid-April and will initially be used to process existing historic Avino mine stock piles left on the surface during our previous operation prior to 2001.

Quality Assurance/Quality Control

Mill assays are performed at the lab onsite at the mine. Check samples are verified by SGS laboratory Services in Durango, Mexico. Concentrate shipments are assayed at AH Knight in Manzanillo, Mexico.

Qualified Person(s)

Avino’s projects are under the supervision of Chris Sampson, P.Eng, BSc, ARSM Avino Consultant and Mr. Jasman Yee P.Eng, Avino director, who are both qualified persons within the context of National Instrument 43-101. Both have reviewed and approved the technical data in this news release.

About Avino

Founded in 1968, Avino’s mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico. We are committed to managing all business activities in an environmentally responsible and cost-effective manner while contributing to the well-being of the community in which we operate.

Avino’s key goal is to become a significant low-cost primary silver producer with specific objectives to: 1) expand resources and reserves, 2) increase the mine’s output, and 3) identify, explore and develop new targets on the property.

ON BEHALF OF THE BOARD

David Wolfin, President & CEO

Safe Harbor Statement – This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including our belief as to the extent and timing of various studies including the PEA, and exploration results, the potential tonnage, grades and content of deposits, timing and establishment and extent of resources estimates. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.

Such factors and assumptions include, among others, the effects of general economic conditions, the price of gold, silver and copper, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations and misjudgments in the course of preparing forward-looking information. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in metal prices; title matters; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers, directors or promoters of with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the our common share price and volume; tax consequences to U.S. investors; and other risks and uncertainties. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Cautionary Note to United States Investors – The information contained herein and incorporated by reference herein has been prepared in accordance with the requirements of Canadian securities laws, which differ from the requirements of United States securities laws. In particular, the term “resource” does not equate to the term “reserve”. The Securities Exchange Commission’s (the “SEC”) disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by SEC standards, unless such information is required to be disclosed by the law of the Company’s jurisdiction of incorporation or of a jurisdiction in which its securities are traded. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. Disclosure of “contained ounces” is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in place tonnage and grade without reference to unit measures.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Avino Silver & Gold Mines Ltd.
David Wolfin
President & CEO
604.682.3701
604.682.3600 (FAX)
ir@avino.com

Gastar Exploration (GST) Declares Monthly Cash Dividend on 8.625%

HOUSTON, April 5, 2013 /PRNewswire/ — Gastar Exploration Ltd. (NYSE MKT: GST) (“Gastar”) announced today that Gastar Exploration USA, Inc., the wholly-owned subsidiary of Gastar, has declared a monthly cash dividend on its 8.625% Series A Preferred Stock (“Series A Preferred Stock”) for April 2013.

The dividend on the Series A Preferred Stock is payable on April 30, 2013 to holders of record at the close of business on April 15, 2013.  The April 2013 dividend payment will be an annualized 8.625% per share, which is equivalent to $0.179688 per share, based on the $25.00 per share liquidation preference of the Series A Preferred Stock.  The Series A Preferred Stock is currently listed on the NYSE MKT and trades under the ticker symbol “GST.PRA.”

About Gastar Exploration
Gastar Exploration Ltd. is an independent company engaged in the exploration, development and production of natural gas and oil in the United States.  Gastar’s principal business activities include the identification, acquisition, and subsequent exploration and development of natural gas and oil properties with an emphasis on unconventional reserves, such as shale resource plays. Gastar is currently pursuing the development of liquids-rich natural gas in the Marcellus Shale in the Appalachia area of West Virginia and, to a lesser extent, central and southwestern Pennsylvania. Gastar also holds prospective acreage in the deep Bossier play in the Hilltop area of East Texas and in the Mid-Continent area of the United States.  For more information, visit Gastar’s website at www.gastar.com.

Safe Harbor Statement and Disclaimer
This news release includes “forward looking statements“ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward looking statements give our current expectations, opinion, belief or forecasts of future events and performance.  A statement identified by the use of forward looking words including “may,“ “expects,“ “projects,“ “anticipates,“ “plans,“ “believes,“ “estimate,“ “will,“ “should,“ and certain of the other foregoing statements may be deemed forward-looking statements.  Although Gastar believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release.  These include risks inherent in natural gas and oil drilling and production activities, including risks of fire, explosion, blowouts, pipe failure, casing collapse, unusual or unexpected formation pressures, environmental hazards, and other operating and production risks, which may temporarily or permanently reduce production or cause initial production or test results to not be indicative of future well performance or delay the timing of sales or completion of drilling operations; delays in receipt of drilling permits; risks with respect to natural gas and oil prices, a material decline in which could cause Gastar to delay or suspend planned drilling operations or reduce production levels; risks relating to the availability of capital to fund drilling operations that can be adversely affected by borrowing base redeterminations by our banks, adverse drilling results, production declines and declines in natural gas and oil prices; risks relating to unexpected adverse developments in the status of properties; risks relating to the absence or delay in receipt of government approvals or fourth party consents; and other risks described in Gastar’s Annual Report on Form 10-K and other filings with the SEC, available at the SEC’s website at www.sec.gov.  Our actual sales production rates can vary considerably from tested initial production rates depending upon completion and production techniques and our primary areas of operations are subject to natural steep decline rates. By issuing forward looking statements based on current expectations, opinions, views or beliefs, Gastar has no obligation and, except as required by law, is not undertaking any obligation, to update or revise these statements or provide any other information relating to such statements.

Contacts:
Gastar Exploration Ltd.
J. Russell Porter, Chief Executive Officer
713-739-1800 / rporter@gastar.com

Investor Relations Counsel:
Lisa Elliott / Anne Pearson
Dennard▪Lascar Associates: 713-529-6600
lelliott@DennardLascar.com / apearson@DennardLascar.com